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1. SUMMARY 
 
Transformed cells undergo profound reprogramming of cellular metabolism to 
ensure high rate of proliferation (Hanahan D, 2011). Mitochondria are important 
for both bioenergetics and biosynthetic pathways, which have to be coordinated. 
Different cancer types heterogeneously express mitochondrial genes likely 
reflecting the existence of different mitochondrial pathways providing 
adaptation to altered needs of cancer cell metabolism. In this work we explored 
this hypothesis in breast cancer.  
Breast cancer is heterogeneous disease classified according to diverse clinical 
and pathological features, histochemical markers and oncogenic transcriptional 
programs, that identify five breast cancer subtypes (basal-like, Her2-enriched, 
Luminal A, Luminal B and normal-like) (Sørlie T et al., 2001; Perou CM et al., 
2000). So far, the mitochondrial transcriptional patterns were not considered as 
a basis of classification. 
In this work we define for the first time breast cancer Mitochondrial Tumour 
Subtypes (MTSs), upper fork (UF) and lower fork (LF), according to their nuclear-
encoded mitochondrial transcription profile. UF and LF are characterised by two 
groups of mitochondrial genes co-regulated in opposite way. The classification 
was performed applying the MCbiclust algorithm (Bentham et al., 2016, preprint) 
to a mitochondrial gene set (MitoCarta, Pagliarini et al., 2008).  
The experimental characterisation of UF and LF revealed distinct bioenergetics 
and metabolic features. Interestingly, in basal condition UF has higher 
mitochondrial content, characterised by higher expression of CI and CIV resulting 
in higher respiration rate. At cellular level metabolism, UF and LF revealed 
different arrangement of metabolic enzymes belonging to particular pathways of 
the intermediate metabolism, UF cells express enzymes of which substrates are 
glucose-derived, whereas LF cells preferentially use enzymes exploiting 
glutamine-derived substrates. Moreover, metabolic flux analysis confirmed the 
substrate preference driven by the MTSs to feed into the TCA cycle, in particular 
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UF cells mitochondria prefer glucose derived pyruvate  while  LF mitochondria 
catabolise glutamine.  
In addition, experiments in restricted nutrient conditions were carried out. These 
further confirmed which is the substrate preferentially used by MTSs to sustain 
cell functionality. Moreover, the same experiments also revealed the activation 
of different mitochondrial biogenesis programs during deprivation treatments, 
both looking at mitochondrial protein expression and mtDNA content.  
Overall, the mitochondrial biogenesis pattern associated with the MTSs drives 
nutrient choice and metabolic program, leading to a definition of the concept of 
substrate preference, new insight in the field of reprogramming of bioenergetics 
and cancer metabolism.  
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2. RIASSUNTO 
 
Le cellule tumorali vanno incontro a profonde modifiche del proprio 
metabolismo cellulare per assicurarsi un alto tasso di proliferazione (Hanahan D, 
2011). I mitocondri sono una sede importante sia per la produzione di energia 
che per i processi biosintetici, pertanto queste vie devono essere 
opportunamente coordinate. Molti tipi di cancro esprimono geni mitocondriali in 
modo eterogeneo, questo probabilmente riflette l’esistenza di diverse vie 
mitocondriali in grado di fornire diverse capacità di adattamento ad un 
metabolismo alterato, come lo è il profilo metabolico associato ai tumori. In 
questo lavoro abbiamo esplorato questa ipotesi nel modello tumorale del cancro 
alla mammella.  
Il cancro alla mammella rappresenta una malattia comunemente classificata sulla 
base di caratteristiche cliniche e patologiche, marcatori istochimici e programmi 
di trascrizione genica che identificano cinque sottotipi di tumore alla mammella 
(basal-like, Her2-enriched, Luminal A, Luminal B e normal-like) (Sørlie T et al., 
2001; Perou CM et al., 2000). Tuttavia, l’espressione di geni mitocondriali non è 
stata finora considerata nella classificazione di questi tumori. 
In questo lavoro definiamo per la prima volta sottotipi tumorali mitocondriali di 
cancro alla mammella (MTSs), upper fork (UF) e lower fork (LF), definiti sulla base 
del loro profilo di trascrizione di geni mitocondriali di codificazione nucleare 
regolati in modo opposto. La classificazione è stata fatta utilizzando l’algoritmo 
MCbiclust (Bentham et al., 2016, preprint) su un set di geni mitocondriali 
(MitoCarta, Pagliarini et al., 2008).  
Dalla caratterizzazione sperimentale di UF e LF sono emerse caratteristiche 
bioenergetiche e metaboliche distintive. In particolare, in condizioni basali UF ha 
un maggiore contenuto mitocondriale, caratterizzato da una maggiore 
espressione dei complessi I e IV  della catena respiratoria, che culmina in un 
tasso di respirazione maggiore. A livello di metabolismo cellulare, UF e LF 
mostrano un diverso assetto di enzimi metabolici appartenenti a particolari vie 
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del metabolismo intermedio. In particolare le cellule dell’UF esprimono enzimi i 
cui substrati sono derivati dal glucosio, mentre le cellule di LF preferiscono 
utilizzare enzimi i cui substrati sono derivati dalla glutammina. Inoltre l’analisi dei 
flussi metabolici ha confermato la preferenza di substrato determinata dai MTSs 
per alimentare il ciclo di Krebs. In particolare i  mitocondri delle cellule dell’UF 
preferiscono il piruvato derivato dal glucosio, mentre i mitocondri di LF 
catabolizzano la glutammina. 
In aggiunta, sono stati eseguiti esperimenti con concentrazioni di nutrienti 
ridotte, i quali, in accordo con i risultati precedenti, hanno ulteriormente 
confermato i substrati preferenzialmente utilizzati dai MTSs per sostenere la 
funzionalità cellulare. Inoltre gli stessi esperimenti hanno rivelato l’attivazione di 
diversi programmi di biogenesi mitocondriale indotti dai trattamenti, sia a livello 
di espressine di proteine mitocondriali che in termini di contenuto di DNA 
mitocondriale. 
Complessivamente, il pattern di biogenesi mitocondriale associato ai sottotipi 
tumorali mitocondriali determina la scelta di nutrienti e programmi metabolici, 
portando così alla definizione del concetto di preferenza di substrato, il quale 
fornisce una nuova visione nel campo della riprogrammazione bioenergetica e 
metabolica del cancro e la possibilità di classificare sottotipi tumorali sulla base 
dell’espressione dei geni mitocondriali. 
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3. INTRODUCTION 
 
3.1 Cancer: the next generation of hallmarks 
Cancer is a heterogeneous disease affecting a large human population; an 
estimated 14.1 million new cancer cases and 8.2 million cancer deaths occurred 
in 2012 worldwide. Lung and breast cancers are the most frequently diagnosed 
cancers and the leading causes of cancer death in men and women, respectively, 
both overall and in less developed countries (Torre LA et al., 2015).  
The alterations in cellular signalling that enable tumour growth and metastatic 
dissemination are often summarised as hallmarks of cancer, currently used to 
define tumours. The classic hallmarks, defined in 2000, include sustained 
proliferative signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis (Hanahan D et al., 2000). Their acquisition is made possible by two 
enabling characteristics: genomic instability, causing mutations and 
chromosomal rearrangement, and inflammation that favour tumour progression 
(Figure3.2) (Hanahan D & Weinberg RA, 2011). Most importantly, it has been 
recently rediscovered that all these hallmarks are intertwined with an altered 
cancer cell-intrinsic metabolism, either as a consequence or as a cause 
(Figure3.1) (Kroemer G & Pouyssegur J, 2008). Indeed, the conceptual progress in 
the last decade suggests that new hallmarks are involved in the pathogenesis of 
the majority of cancers: reprogramming of energy metabolism, in order to most 
effectively support neoplastic proliferation, and the active evasion by cancer cells 
from attack and elimination by immune cells (Figure 3.2) (Hanahan D & 
Weinberg RA, 2011). Further complexity is added by the concept of tumour 
microenvironment, in which a repertoire of cells can contribute to the 
acquisition of the hallmarks themselves (Figure 3.2) (Hanahan D & Weinberg RA, 
2011). 
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Overall, this scenario appears very complex. Since the main topic of the thesis is 
cancer metabolism, here I will focus on introducing the concept of metabolic 
reprogramming. 
 
 
Figure 3.1 The hallmarks of cancer and their link to tumour metabolism (Kroemer G & Pouyssegur 
J, 2008). 
 
 
 
Figure 3.2 Emerging hallmarks, enabling characteristics and tumour microenvironment (Hanahan 
D & Weinberg RA, 2011). 
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3.1.1 Reprogramming of cellular metabolism and bioenergetics 
Several findings indicate that cancer cells undergo a complex metabolic 
reprogramming to satisfy the increased requirement of macromolecules and 
energy necessary for proliferation.  
The first alteration of cancer metabolism was observed by Otto Warburg in the 
1920s, when he observed that tumour cells consuming large amounts of glucose 
through glycolysis even in the presence of oxygen, a phenomenon since known 
as aerobic glycolysis or Warburg effect, whereas normal cells predominantly use 
respiration as main energy source (Warburg et al., 1927) (Figure 3.3). To explain 
this phenomenon in which cancer cells limit their bioenergetics to glycolysis, he 
hypothesized that cancer transformation was caused by defects in mitochondrial 
function (Warburg, 1956). However, it is now clear that respiration is not 
impaired in most cancer cells (Wallace DC, 2012; Lunt SY et al., 2011). Hence, the 
explanation for the switch to aerobic glycolysis in cancer cells is to support the 
anabolic requirements associate with cell growth and proliferation, providing 
glycolytic intermediates for biosynthesis (Ward PS and Thompson CB; 2012; Lunt 
SY et al., 2011; Vander Heiden MG et al., 2009). 
 
 
Figure 3.3 Schematic differences between oxidative phosphorylation, anaerobic glycolysis and 
aerobic glycolysis (Vander Heiden et al., 2009). 
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The concept has evolved in the following decades highlighting that mitochondrial 
function is essential for cancer cells (Wallace DC, 2012) and in this context 
oncogenes (e.g. c-MYC, K-ras, PI3K) play an active role in the metabolic rewiring 
(reviewed in Ward PS &Thompson CB, 2016; Boroughs LK & DeBerardinis RJ, 
2015; Pavlova NN & Thompson CB 2012). Furthermore, metabolites themselves 
can promote tumorigenesis by altering the epigenome, defining a concept of 
oncometabolites (reviewed in Nowicki S & Gottlieb E, 2015). To sustain cell 
growth, cancer cells need to take up nutrients from the environment as source of 
energy and building blocks, among which glucose and glutamine are 
fundamental nutrients. Glucose is an energetic source as it supplies carbons, 
whereas glutamine is apart from providing carbon is also the unique source of 
nitrogen for cancer cells (DeNicola GM & Cantley LC, 2015; Lunt SY, Vander 
Heiden MG, 2011) (Figure 3.4). Overall, the concept of cancer metabolism is a 
leading-edge theme subjected to intense study.  
 
 
 
Figure 3.4 Contribution of glucose carbons as well as glutamine carbons and nitrogens to biomass 
lactate and CO2 in a proliferating cell (Lunt SY et al., 2011). 
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3.2 Mitochondrion: a key player in orchestrating metabolism 
The intermediate metabolism comprises the catabolic and anabolic reactions 
happening inside the cells, that produce energy and reducing equivalents 
(NAD(P)H) to sustain synthesis of new macromolecules. All these reactions 
support cell proliferation (Figure 3.5).  
 
 
 
Figure 3.5 Metabolic pathways acting in proliferating cells  (Lunt SY et al., 2011). 
 
The reactions involve spatially separated enzymes, which localise in the 
cytoplasm or inside mitochondria. However, the two compartments are kept in 
connection due to the presence of transporters and shuttle systems. 
Normally, glucose is oxidised by glycolysis to produce pyruvate which enters into 
mitochondria through the mitochondrial pyruvate carriers (MPC1 and 2) (Bricker 
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DK et al., 2012; Herzig S et al., 2012) and fuels the TCA cycle and consequently 
oxidative phosphorylation (OXPHOS) culminating in ATP production. 
Furthermore, the glycolytic intermediates can be shunted to the pentose 
phosphate pathway (PPP), producing NADPH and ribose-5 phosphate later sorted 
for nucleotide biosynthesis. Similarly, the TCA cycle intermediates are utilised as 
substrates for biosynthetic reactions, requiring  specific shuttle (malate-aspartate 
shuttle) and transporters to move outside mitochondria. However, in order to 
coordinate biosynthetic needs and respiration, they have to be replenished, a 
phenomenon known as anaplerosis (Metallo CM & Vander Heiden MG, 2013)  
(Figure 3.6). The main anapletoric substrates for the TCA cycle are glucose-
derived pyruvate and the amino acid glutamine, that act as both catabolic and 
anabolic substrates. 
 
Figure 3.6 The mitochondria connection with the spatially separated reaction  
of the intermediate metabolism. 
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Overall, mitochondria play a central role in orchestrating metabolism through a 
coordination of bioenergetics and biosynthetic pathways. 
This concept is particular important in cancer cells in which a metabolic 
reprogramming occurs. Indeed, given the importance of mitochondria in 
bioenergetics and metabolism, cancer cells need to maintain a functional 
mitochondrial pool to cope the energetic and metabolic requirements and thus 
sustain cell proliferation. Mitochondrial biogenesis is the process responsible in 
the maintenance of the mitochondrial pool. 
 
3.3 Mitochondrial biogenesis 
3.3.1 General framework 
The mitochondrion represents a unique organelle within the complex 
endomembrane systems that characterize any eukaryotic cell. Beyond the pivotal 
role they play in ATP production, a whole new mitochondrial biology has 
emerged in the last few decades: mitochondria have been shown to participate 
in many other aspects of cell physiology such as amino-acid synthesis, iron-
sulphur clusters assembly, lipid metabolism, Ca2+ signaling, reactive oxygen 
species (ROS) production and cell death regulation.  
Hence, many pathological conditions are associated with mitochondrial 
dysfunction, including neurodegenerative diseases (Alzheimer’s, Parkinson’s, 
Hungtinton’s), motoneuron disorders (amyotrophic lateral sclerosis, type 2A 
Charcot-Marie-Tooth neuropathy), autosomal dominant optic atrophy, ischemia-
reperfusion injury, diabetes, ageing and cancer (Duarte et al., 2014; Gaude and 
Frezza, 2014).  
Understanding how mitochondria can sense and decode various signals from the 
cytosol and other subcellular compartments represents a new exciting challenge 
in biomedical research.  
Mitochondria are defined by two structurally and functionally different 
membranes: the plain outer membrane (OMM), permeable to ions and 
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metabolites up to 5000 Da, and the highly selective inner membrane (IMM), 
characterized by invaginations called cristae which enclose the mitochondria 
matrix. The space between the two membranes is called intermembrane space 
(IMS). The cristae define internal compartments formed by profound 
invaginations originating from narrow tubular structures called cristae junctions 
(Mannella, 2006) that limit the diffusion of molecules from the intra-cristae 
space towards the IMS, thus creating a micro-environment where the 
mitochondrial Electron Transport Chain (mETC) complexes are hosted and other 
proteins are protected from random diffusion. Inside the mitochondrial matrix 
there is the mitochondrial genome, called mitochondrial DNA (mtDNA); there are 
also mitochondrial ribosomes and 22 transfer RNAs (tRNAs), the machinery  
responsible for nucleus-independent protein synthesis.  
 
3.3.2 Mitochondrial biogenesis process 
The mitochondrial proteome consists of around 1098 proteins of which 
expression vary among different tissues (Pagliarini et al., 2008). Mitochondria are 
continuously remodeled by a dynamic process of fusion and fission, occurring 
with mtDNA synthesis, protein synthesis inside mitochondria and protein import 
from the cystosol. Interestingly only 13 proteins, that function as essential 
subunits of respiratory complexes I, III, IV and V, are encoded by the mtDNA. The 
mtDNA-encoded proteins are expressed through the bidirectional synthesis of 
multigenic transcripts, followed by the processing, polyadenylation and 
translation of individual mRNAs (Taanman JW et al., 1999). Mitochondrial 
transcription requires a single RNA polymerase (POLRMT), initiation (TFB2M) and 
stimulatory (Tfam) transcription factors and a family of termination factors 
(mTERFs) (Bonawitz ND et al., 2006; Scarpulla RC, 2008a). However, the majority 
of mitochondrial proteins are encoded in the nucleus, rendering the 
mitochondrial biogenesis process primarily regulated at the nuclear 
transcriptional level (Scarpulla RC, 2011; Scarpulla RC, 2008a).  
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A plethora of transcription factors (TFs) and nuclear receptors (NRs) regulates 
the process in hierarchical manner, among which NRF 1 and 2, CREB, YY1, , c-
MYC ERR, PPAR family. The presence of transcriptional co-regulators (TCRs) of 
the PGC-1 family (PGC-1α, PGC-1β and PRC) modulates their activity. 
 
 
 
Figure 3.7 Mitochondrial biogenesis a process.  
 
 
TFs and NRs directly bind DNA promoter regions activating transcriptional 
programs. 
The nuclear respiratory factors 1 and 2 (NRF1, NRF2) are responsible for the 
induction respectively of the cytochrome c and cytochrome oxidase subunit 
genes. The two factors frequently work in conjugation in the expression of many 
nuclear genes specifying essential mitochondrial function  (Scarpulla RC, 2008a; 
Scarpulla RC, 2008b). Moreover, NRFs indirectly control the expression of mtDNA 
by regulating the Tfam expression.  
cAMP response element binding protein CREB, are involved in the expression of 
mitochondrial genes in response to cyclic adenosine monophosphate (cAMP), a 
second messenger derivative of ATP used for intracellular signalling. Importantly, 
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it has been found to bind the PGC-1α promoter and directly regulate its 
expression (Herzig et al. 2001). CREB is also involved in general processes such as 
cell proliferation, differentiation and adaptive responses and much more specific 
roles such as in the development of memory (Shaywitz 1999). 
Yin Yang 1 (YY1) is a transcription factor, that has been implicated in regulation 
of cyctochrome c oxidase subunits (Scarpulla 2008). Moreover, it has been 
shown by Cunningham et al. (2007) to form a complex with PGC-1a in muscle to 
regulate 40 mitochondrial gene expression. Importantly, YY1 requires the activity 
of the protein mammalian target of rapamycin (mTOR), known to regulate many 
cellular processes involved in cell growth. In addition, mTOR is often described as 
a nutrient sensor, providing a link between nutrient sensing pathways and 
mitochondrial biogenesis. 
c-Myc  is a transcription factor involved in cell cycle regulation, apoptosis and 
cellular transformation and has been identified as an oncogene being commonly 
mutated in many types of cancer promoting cancer metabolic reprogramming 
(Hsieh AL, et al., 2015, Dang 2012). Myc plays an important role in mitochondrial 
biogenesis, indeed evidences showed that myc null fibroblast are deficient in 
mitochondrial content (Li F et al., 2005). 
The estrogen related receptors family composed by ERRα, ERRβ, ERRγ, known 
also as orphan receptors because of the structural similarity to the estrogen 
receptors but lacking of ligands, are differently expressed in the tissues. ERRα is 
the ubiquitous member, which is known to regulate genes involved in lipid 
oxidation, OXPHOS, the TCA cycle, mitochondrial import and dynamics as well as 
response to oxidative stress (Hock 2009). Moreover, the transcriptional activity 
seems to be dependent on their relationship with PGC-1a and PGC-1b (Huss et al. 
2015). 
The PPAR family is a group of nuclear receptors highly involved in the regulation 
of mitochondria biogenesis. The PPAR family members, PPARα, PPARδ also 
referred to as PPARβ and PPARγ, have distinct tissue distributions as well as 
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physiological functions. PPARδ and PPARγ is also thought to regulate co-activator 
PGC-1α via a PPAR response element. 
The involvement of transcriptional co-regulators in the mitochondrial biogenesis 
has been appreciated by the discovery of the nuclear co-activator PPARγ co-
activator-1α (PGC-1α). Co-regulators function in  large multiprotein complexes; 
they do not directly bind to DNA, but rather they engage TFs and NRs modulating 
their transcriptional activity (activation or repression). 
The PGC-1 family of co-activators are composed by PGC-1α, which has the first 
been discovered as co-regulator of PPARγ and NRs during adaptive 
thermogenesis in mouse brown adipocytes and skeletal muscle (Puigserver P et 
al., 2000), and the structurally related transcriptional coactivator PGC-1β, 
characterized by having PGC-1α complementary function, and PGC-1α related 
coactivator (PRC). Moreover, new complexity was added by the discovery of 
alternative splicing variants in the PGC-1α gene (Ruas JL et al., 2012; Zhang Y et 
al., 2009). In literature PGC-1 family as referred the ‘master regulator’ of 
mitochondrial biogenesis (Jones AW, 2012; Scarpulla 2011).  
Interestingly, the PGC-1 family is responsible for the regulation of a broad range 
of metabolic functions intrinsic, but not only, to mitochondria. In particular, a 
couple of examples are reported for the main member PGC-1α, which was found 
by Mootha et al., 2003 to activate a large set of genes expressing OXPHOS 
proteins, mediating insulin-dependent glucose disposal; moreover, PGC-1α 
coordinates triglyceride metabolism (Zhang Y et al., 2004).  
The activity of PGC-1 family are in turn modulated by a range of cellular signaling 
pathways, through the regulation of PGC-1 expression levels or post-translational 
modification.  
These co-regulators behave like a sensors and they can be influenced by 
metabolic signals and stress signals, thus modulating the mitochondrial 
biogenesis. For instance, energy deprivation, represented by decreased 
ATP/AMP and NADH/NAD+ ratios, activates PGC-1α through both the 
phosphorylation via AMP activated protein kinase (AMPK) pathway or by sirtuin 
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(SIRT1) mediated deacetylation.  The cellular energy status acts on PGC-1α also 
through the mammalian target of rapamycin (mTOR) (Hock MB and Kralli A, 
2009).  
Interestingly, PGC-1α has been found altered also in cancer; the promoting 
tumour growth by inducing gene expression programs supporting lipogenesis  
(Bhalla K et al., 2011) is only an example. 
 
 
Figure 3.8 The central role of PGC-1α in the regulation of mitochondrial biogenesis (Scarpulla, 
2011). 
 
3.4 Breast cancer 
Breast cancer is one of the most common forms of cancer in women worldwide, 
but it can arise also in men, even if it is rare. Each year, the American Cancer 
Society estimates the numbers of new cancer cases and deaths that will occur in 
the United States in the current year and compiles the most recent data on 
cancer incidence, mortality, and survival. In 2015 Siegel, RL et al. has estimated 
249,260 new breast cancer cases, comprising both sex, of which 40,890 
estimated death in 2016. 
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Breast cancer is a heterogeneous group of diseases with different histological, 
prognostic and clinical aspects. Breast tumours are classified according to 
important clinical features, such as the age of the patient, the tumour stage (I, II, 
III), the cancer type (ductal, lobular, ductal and lobular, inflammatory), the 
histological grade, tumour size and the lymph node status that give information 
on the spreading of cancer cells, finally the tumour subtypes. The three different 
histological grades are based on the appearance of the cancer cells, grade I refers 
to cells which look similar to normal cells and are slow growing, grade II refers to 
cells that are abnormal and are growing at an increased rate, while grade III 
refers to cells that look very abnormal and are growing quickly. These clinical 
phenotypes, tumour size, tumour grade and the lymph node status, are used to 
calculate the Nottingham prognostic index (NPI) which is exploit to assign a 
probability of 5-year-survival.  
In addition, breast cancer is further classified according to the expression of 
pathological markers, that can be up-regulated in breast cancer and of which 
expression is evaluated by histochemical analysis: the estrogen receptor (ER), the 
progesterone receptor (PR) and the human epidermal growth factor receptor 2 
(HER2), each driving a particular transcriptional program. According to the 
expression status, breast cancers are classified as ERs positive or triple negative, 
that determine a different prognosis.  
Further complexity was added by the analysis of gene expression data; according 
to the expression profile five subtypes have been identified: basal-like, Her2-
enriched, Luminal A, Luminal B and normal-like (Sørlie T et al., 2001; Perou CM et 
al., 2000). Moreover, a set of 50 genes (PAM50) were selected to help clinician in 
the assignment of samples to belonging to basal-like, luminal A, luminal B, HER2-
enriched or normal-like tumours and leading to the choice of the beast 
treatment (Parker JS et al., 2009). 
So far, no studies have involved the analysis of mitochondrial genes in the 
classification of breast cancer. 
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3.5 Massively correlated biclustering: MCbiclust 
Currently, novel high-throughput technologies have produced a huge amount of 
transcriptional data, also in the field of breast cancer (T.C.G.A. Network, 
“Comprehensive molecular portraits of human breast tumours” Nature 2012). 
The requirement to analyse and extrapolate information from this complex mass 
of data continue to lead the development of new software. For this purpose, our 
collaborator Robert Bentham developed a new algorithm named Massively 
Correlated Biclustering algorithm, MCbiclust (Bentham et al., 2016), which 
simultaneously clusters genes and samples to find hidden structures in the data. 
The approach shows advantages comparted to the previous ones used until now: 
(i) it is computationally efficient to be applied to large data matrices containing 
whole genome transcriptomic data of more than a thousand samples; (ii) it is 
capable to identify correlated, biologically relevant large gene sets and subsets of 
heterogeneous samples where the gene set is being differentially regulated. The 
method addresses key question in genome biology, in particular it has been 
evaluated using synthetic data and applied to large bacterial and cancer cell 
datasets. The large biclusters discovered, so far elusive to identification by 
existing techniques, were found biologically relevant. Thus, MCbiclust has a great 
potential use in the analysis of transcriptomic data to identify large scale 
unknown effects hidden within the data (Bentham et al., 2016). Further details 
on the method are explained in the paper Bentham et al., 2016. The software is 
available as a Bioconductor package in R.  
We exploited this tool in our study on breast cancer, to transcriptionally identify 
mitochondrial tumour subtypes, which have been characterised in this project. 
R package 
Custom made algorithm and associated methods for finding, visualising and 
analysing biclusters in large gene expression data sets. Algorithm is based on 
with a supplied gene set of size n, finding the maximum strength correlation 
matrix containing m samples from the data set. 
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Author: Robert Bentham 
Maintainer: Robert Bentham <robert.bentham.11 at ucl.ac.uk> 
Citation (from within R, enter citation("MCbiclust")): 
Bentham R (2017). MCbiclust: Massive correlating biclusters for gene expression 
data and associated methods. R package version 0.99.41. 
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4. AIM OF THE WORK 
 
During tumorigenesis, different stressors, among which oncogenes and 
metabolic stressors, force cells to adapt. The induction of specific genes can 
highlight the presence of a specific transcriptional programs that influence cell 
function and viability.  
Recently, cancer metabolism has gained interest, due to the understanding that 
its alteration might not be simply a consequence of oncogene activation, but 
might play an active role. Metabolism is tightly linked to cellular bioenergetics, 
thus reprogramming of cellular metabolism and bioenergetics occurs together 
during cellular transformation. In this context mitochondria have a central role; 
indeed in the mitochondria the oxidative phosphorylation with energy 
production takes place, intimately linked to metabolic pathways, in particular the 
TCA cycle. In turn, mitochondrial transporters and shuttles move TCA cycle 
intermediates from mitochondria to cytoplasm and vice versa, participating in 
the whole cell metabolic network. 
The hypothesis: Mitochondrial gene expression and function drives tumour 
adaptation and evolution, so the adaptive process induces specific mitochondrial 
gene expression pattern and related metabolic programs. Mitochondria act as 
sensor and play an active and plastic role in the adaptation.  
Our work was aimed to distinguish tumour subtypes, characterised by a specific 
mitochondrial pattern that we call mitochondrial tumour subtypes (MTSs). In 
order to achieve this aim, we took advantage of the MCbiclust algorithm to 
analyse breast cancer transcriptomes and identify biclusters of which a pattern 
could underlie a specific transcriptional program. Following the transcriptional 
identification of MTSs, we performed functional verification of the MTS 
subtypes. In particular, cellular metabolism and bioenergetics were analysed in 
order to identify signalling and metabolic pathways peculiar of MTSs. 
My PhD project focused on reprogramming of cellular metabolism and 
bioenergetics in breast cancer models of the newly identified mitochondrial 
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tumour subtypes. We evaluated bioenergetics by measuring mitochondrial 
proteins involved in the energy production and testing the mitochondrial 
function. We looked at metabolism, analysing the expression of metabolic 
enzymes at both protein and transcriptional level, finally concluding with 
metabolic fluxes analysis. In addition we mimic a nutrient-deprived environment 
to evaluate the acute response and the adaptation. We assessed the 
mitochondrial health through the analysis of the steady state mitochondrial 
membrane potential. Then we looked for evidences which could indicate that 
mitochondrial biogenesis process was turn on. For that, we measured the mtDNA 
content, the expression of mitochondrial proteins important for the energy 
production and the ATP production itself. 
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5. MATERIALS AND METHODS 
 
5.1 Cell cultures 
Five breast cancer cell lines were used to perform experiments in this work: 
MCF7, HCC202, MDA-MB453, Hs578T, MDA-MB436. All the cell lines were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) (cat# 41966-029, ThermoFisher), 
supplemented with 10% Fetal Bovine Serum (FBS) (cat# 10500-064, 
ThermoFisher) and 10% Normocin (cat# ant-nr-1, Labogene). Cells were 
maintained in culture in a 37°C incubator set with 5% CO2 and 95% humidity. 
The right cell number necessary for each experiment was counted using the 
hemocytometer. 
 
5.2 Deprivation treatment 
For the deprivation treatment, cells were incubated with medium containing 
reduced either glucose or glutamine, with or without pyruvate. All the media, 
composed by a combination of different nutrients concentration, were prepared 
starting from a Dulbecco’s modified Eagle’s medium (DMEM) no glucose, no 
phenol red, no glutamine (cat# A14430-01, ThermoFisher), supplemented with 
10% Fetal Bovine Serum (FBS) (cat#, 10500-064 ThermoFisher) previously 
dialysed with SnakeSkin™ Dialysis Tubing, 3,5K MWCO, 35 mm dry I.D., 35 feet 
(cat# 88244, ThermoFisher) in sterile Phosphate Saline Buffer (PBS1X) (cat#, 
20012-019 ThermoFisher) in the proportion of 50mL of serum per 5L of PBS1X. 
The glucose powder suitable for cell culture (cat# G7021, Sigma) were weight to 
reach the final concentration of 25mM, 10mM, 0.75mM; the same was done for 
the Sodium Pyruvate (cat# P2256, Sigma) and Phenol Red powders (cat# P3532, 
Sigma) to obtain the concentration of use respectively of 1mM and 0.04mM. 
Finally the sterile stock glutamine solution (cat# 25030-024, ThermoFisher) were 
diluted to the final concentration of 2mM or 0.2mM. The obtained solutions 
were filtered using 0.22µm sterile filter to guarantee the medium sterility. 
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5.3 Cell growth 
5.3.1 Counts  
To build growth curves, 12-well plates were used. Each plate were seeded with 
one cell line at a dilution of 4K cells per well, to test three different glucose 
concentrations in triplicate: glucose 10mM, glucose 0.75mM, galactose 10mM 
(glucose 0mM), all of them containing normal glutamine (2mM), supplemented 
or not with pyruvate 1mM. The time course was of 19 days: the seeding at day 1 
was executed using a DMEM, high glucose, GlutaMAX™ Supplement, pyruvate 
(cat# 31966-047 Thermo Fischer); deprivation treatment at day 4 was done by 
substituting the medium with experimental one after washing  twice with sterile 
PBS1X (cat# 20012-019, Thermo Fischer); cell counting at day 6, 12 and 19 was 
done trypsinising and determining the cell number by hemocytometer. The 
entire protocol was repeated for all the five cell lines utilised in this work. Then 
the average of the three technical replicates for each condition in all the cell 
types was calculated and the results was plotted on the XY chart as a function of 
the days; finally a doubling time was estimated, and a ratio between doubling 
time calculated. 
 
5.3.2 Imaging 
Cell proliferation was measured in a time course of 8 days, using 96-well plates; 
on each plate four cell lines were seeded (MCF7, HCC202, Hs578 T, MDA-MB 
436) in triplicate for all the deprivation treatment tested (HH: glucose 25mM, 
glutamine 2mM; HL: glucose 25mM, glutamine 0.2mM; LH: glucose 0.75mM, 
glutamine 2mM; LL: glucose 0.75mM, glutamine 0.2mM; all of them 
supplemented (+) or not (-) with pyruvate 1mM). The seeding and the treatment 
was done respectively at day -1 and day 0 and the cell number was evaluated at 
day 2, 4, 6 and 8. Imaging was done using ImageXpress Micro XL high content 
imaging system. The resulted cell number/fild was plotted as a function of the 
days. 
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5.4 Western blotting 
This technique was used to evaluate the endogenous expression of proteins in 
our experimental models in normal culturing conditions and during deprivation 
treatment. Cells were lysated in RIPA-buffer (150 mM NaCl, 50 mM Tris, 1 mM 
EGTA, 1% Triton X-100, 0.1%SDS) containing ROCHE inhibitors cocktails; after 30’ 
of  incubation on ice the protein lysates were quantified using Pierce BCA protein 
assay kit (reagent A cat# 23228, reagent B cat# 23224 Thermo Scientific) 
according to the manufacturer’s instructions. Samples were then prepared for 
loading with loading buffer and denatured by boiling at the appropriate 
temperature for each antibody used (10’ at 60°C for MitoProfile; 5’ at 90°C for all 
the other antibodies). Samples were loaded in the amount of 20µg per well in 4-
12% BisTris NuPAGE gel (cat# NP0321BOX Thermo Fischer) and run at 150V in 
MOPS running buffer until reaching the bottom of the gel. For the blotting, 2h at 
30V, a PVDF membrane and the Life Technologies wet system were used. The 
PVDF was first pre-soak in methanol for the activation and then in the transfer 
buffer. Successively, a Ponceau-S staining was done to check the protein 
transferring and the membranes were blocked for one hour at room 
temperature in Tris-buffered saline (TBS)(Tris 0.5M - NaCl 1.5M)- Tween 0.1% 
and 5% milk. An appropriate dilution of primary antibody was used to incubate 
the membrane overnight at 4°C. Horseradish peroxidase-conjugated secondary 
antibody was applied for 1h at RT. After each antibody incubation, three washes 
of 5’ were done with TBS-Tween 0.1% on an orbital shaker. To revel the 
membrane a Super Signal West Pico Chemiluminescent Substrate (Thermo 
Scientific) was used according to manufacturer’s instructions. The obtained 
images was analysed using ImageJ (downloadable for free). 
We used the following antibodies: MitoProfile® Total OXPHOS Rodent WB 
Antibody Cocktail (1:2000, Miotsciences #MS604,), which recognises one subunit 
of each respiratory chain complex (CI subunit NDUFB8, CII-30kDa, CIII-Core 
protein 2, CIV subunit I, CV alpha subunit. The mAbs in the cocktail were chosen 
because they are against a subunit that is labile when its complex is not 
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assembled); anti-HK1, anti-HK2, anti-PKM1 and anti-PKM2 (all 1:1000, Cell 
Signalling respectively #2024, #2867, #4053, #7067); anti-TPI, anti-PDH-E1alpha, 
anti-IDH2, anti-ME1, anti-PPAT, anti-GLS1, anti-GLUD, anti-GFPT1 and anti GFPT2 
(all 1:1000, Abcam respectively #ab135532, #ab110330, #ab55271, #ab97445, 
#ab128116, #ab93434, #ab166618, #ab125069, #ab190966); anti-IDH1, anti-
PSAT1, anti-GOT1 (all 1:1000, Proteintech respectively #12332-1-ap, #20180-1AP, 
#14986-1AP); anti-PHGDH (1:1000, Santa Cruz #sc292792); anti-GS (1:1000, BD 
Biosciences #610518); secondary HRP-conjugated antibodies (all 1:5000, BioRad 
anti-rabbit #170-6515, anti-mouse #170-6516). 
 
5.5 ATP measurements 
The ATP levels were evaluated using a Luiferin/Luciferase based approach. In our 
study, the CellTiter-Glo® Luminescent Cell Viability Assay (cat# G7572, Promega) 
was used. The method determines the number of viable cells in culture based on 
the quantitation of the ATP present, which signals the presence of metabolically 
active cells, in our case it was chosen with the aim to estimate the ATP produced 
by a known number of seeded cells and compare the results among cell types. It 
consists in a one-shot reaction; indeed, after the addition of the reconstituted 
reagent, cell lysis and generation of a luminescent signal proportional to the 
amount of ATP present occur. The assay relies on the properties of a 
thermostable luciferase (Ultra-Glo™ Recombinant Luciferase), which generates a 
stable “glow-type” luminescent signal. The luciferase reaction consists in the 
mono-oxygenation of beetle luciferin catalysed by Ultra-Glo™ Recombinant 
Luciferase in the presence of Mg2+, ATP and molecular oxygen with a production 
of oxyluciferin AMP, PP, CO2 and light emission. The manufacturer’s instructions 
suggested the following technical protocol: 1- after adding the test compound, 
equilibrate the plate and its contents at room temperature (RT) for 
approximately 30 minutes, avoiding temperature gradients which could cause 
uneven signals; 2- add a volume of CellTiter-Glo® Reagent equal to the volume of 
cell culture medium present in each well (e.g., add 100μl of reagent to 100μl of 
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medium containing cells for a 96-well plate); 3- mix contents for 2 minutes on an 
orbital shaker to induce cell lysis; 4-to incubate the plate at RT for 10 minutes to 
stabilize luminescent signal; 5- record luminescence. 
In this work, the ATP production was evaluated after 30’ and 24h of deprivation 
treatment with the following media: HH -/+; HL -/+; LH -/+; LL -/+. In details, at 
day -1 5K cells of MCF7, HCC202, Hs578 T, MDA-MB-436 cell lines were seeded in 
opaque black 96-well plate in double, two plate-lines per cell type except for the 
last column of the plate, on which the blank (for removing the medium 
background during data analysing) and the ATP standard of 10mM (on which the 
samples luminescent was normalised to) were loaded. At day 0 the treatment 
was applied for 30’ and 24h per each condition (every plate with one 
combination of glucose and glutamine, with and without pyruvate, e.g., HH+ and 
HH-). After the deprivation treatment and before measuring the ATP levels, in 
order to discriminate the contribution of mitochondria and glycolysis to the ATP 
production, cells were treated with the ATP synthase inhibitor oligomycin at a 
concentration of 10µM, or with the glucose analogue 2-deoxiglucose (cat# 
D8375, Sigma) (2-DG, lacking of the 2-hydroxyl group replaced by hydrogen) 
which is not processed through glycolysis, at a concentration of 10mM. 
Moreover the combination of both compounds was applied to completely 
abolish the ATP production and the resulted values used to exclude the internal 
background during the analysis. The media containing inhibitors was prepared 
using a serum-free DMEM no glucose, no phenol red, no glutamine, 
supplemented with HEPES 10mM at pH7.4. The glucose and glutamine 
concentration and the presence or not of pyruvate was determined by the 
deprivation treatment previously done on each plate; moreover when the 
glycolytic inhibitors 2-DG was used, glucose was not added to the medium 
containing inhibitor. The treatment with the inhibitors was done for 30’ at room 
temperature, allowing in this manner also the RT equilibration of the plate, as 
suggested by the manufacturer’s instructions as described at the beginning of 
this paragraph. The luminescence was recorded using PerkinElmer EnVision plate 
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reader. Finally, protein content of each well were evaluated using the BCA 
protein assay as index of the cell content per well. 
For each plate the triplicate values for the total ATP produced (no inhibitors 
added), the amount of ATP after oligomycin and 2-DG treatments was obtained; 
the duplicate values was recorded for the oligomycin/2-DG inhibition; triplicate 
values for the ATP standard and five replicates of medium luminescence for the 
background were acquired. The average of the replicates was calculated and the 
background was subtracted. The resulted values were normalised to the ATP 
standard previously adjusted for the background and further normalised to the 
protein content. 
Data analysis showed fluctuation in the values produced by the treatment of the 
combination of the two inhibitors olygomicin and 2-DG, consequently these data 
couldn’t be used to remove the internal background. To overcome the problem 
the data were analysed as described in the scheme of the figure 6.4.2D. 
 
5.6 Oroboros assay 
Oxygen consumption rates were measured in collaboration with Cathy Qin, an 
undergraduate medical student at UCL London, using an Oroboros Oxygraph-2k 
high resolution respiratory system. Cells were grown to confluency in 10cm 
plates for 48 hours prior to the assay. The cells were diluted to 1 million cell/ml 
in a respiration buffer (DMEM powder (8.3g/L), sodium pyruvate (110mg/L), 
glucose (1000mg/L), Glutamax 100x (10ml/L), Sodium bicarbonate (3.7g/L), FBS 
10% and media adjusted to 7.4pH and filter sterilised with a 0.22 Stericup). Prior 
to the assay, electrode air calibration was performed with the respiration buffer, 
as suggested by manufacturer’s protocol. 2ml of the cell suspension were added 
to each of the two chambers, and the O2 flow signal allowed to stabilise to the 
basal respiration rate. Drugs were added to the chambers using Hamilton 
syringes at the following concentrations and order: oligomycin (2.5μM), 
carbonylcyanide-p-(trifluoromethoxy)-phenylhydrazone (FCCP) (titrated 1μl at a 
time from a 1mM stock, to produce maximal respiratory capacity), and antimycin 
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A (2.5μM). Oligomycin inhibits adenosine triphosphate (ATP) synthase and 
therefore blocks the main proton channel into the mitochondrial matrix, the 
resulting respiration rate is due to the proton leak in the inner mitochondrial 
membrane. FCCP uncouples the inner mitochondrial membrane allowing protons 
to freely pass across the membrane. This equalises the mitochondrial membrane 
potential but also leads to the flow of electrons in the ETC not being dependent 
on the number of protons in the mitochondrial matrix. This results in a maximal 
respiration rate where the ETC is not limited by the number of protons in the 
mitochondrial matrix. Antimycin A inhibits cytochrome C reductase otherwise 
known as Complex III in the ETC. This stops all oxygen consumption from the 
mitochondrial and gives us a value for non-mitochondrial respiration that can be 
subtracted from the basal, leak and maximal rates to give mitochondrial specific 
rates. Data were then extracted and analysed using O2K cell analysis template to 
give oxygen consumption per unit cells. Significance between different groups 
was then tested by one-way analysis of variance (ANOVA). 
 
5.7 Mitochondrial membrane potential measurement  
The measurement of mitochondrial membrane potential is based on the 
distribution of the mitochondrion-selective lipofilic cation ”tetramethyl 
rhodamine methyl ester” dye (TMRM, Life Technologies). It is fluorescent and 
membrane permeable and its distribution into intracellular compartments is 
triggered by electrochemical gradients. Hence, at low concentrations, its 
accumulation into mitochondria was shown to be driven by mitochondrial 
membrane potential (almost -180mV). In order to promote the correct 
distribution of the probe, cells were loaded with the dye-solution at very low 
concentration. Changes in mitochondrial membrane potential cause a 
redistribution of the dye between mitochondria and cytoplasmic environment.  
In our work, Δψm of four cell lines (MCF7, HCC202, MDA436, Hs578T), treated 
with 8 different deprivation treatment (HH -/+; HL -/+; LH -/+; LL -/+), was 
evaluated. The same time course protocol of 8 days used for imaging the cell 
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growth (paragraph 5.3.2) was applied also in this case. Cells were loaded with 
TMRM solution. The probe was excited at 560 nm and the emission light was 
recorded in the 590-650 nm range. FCCP (carbonyl cyanide p-
trifluoromethoxyphenylhydrazone, 10 μM), an uncoupler of oxidative 
phosphorylation, was added to completely collapse the electrical gradient 
established by the respiratory chain (ΔΨ). Data are expressed as difference 
between the TMRM fluorescence before and after FCCP depolarization. 
ImageXpress Micro XL high content imaging system was used in TMRM 
experiments. 
 
5.8 Mitochondrial biogenesis determination 
Mitochondrial biogenesis can be evaluated at different levels among which 
mitochondrial proteins and mitochondrial DNA (mtDNA) content.  
The first aspect was evaluated by measuring the protein levels of respiratory 
chain complexes at normal culturing condition and after glucose deprivation 
treatment. The seeding protocol, the time course and the media was the same of 
which used to build the growth curve by counts (paragraph 5.3.1); at day 19 cells 
were collected and processed by western blotting analysis using the MitoProfile 
antibody cocktail (paragraph 5.4). 
The mtDNA content was determined by imaging. The protocol used was the 
same applied for the imaging of cell growth and Δψm: time course of 8 days and 8 
different deprivation treatments (HH -/+; HL -/+; LH -/+; LL -/+). Before imaging 
by ImageXpress Micro XL high content imaging system, cells were labelled with 
Hoechst, TMRM and picoGreen to see respectively the nuclei, mitochondria and 
dsDNA, in this case mtDNA. From the Hoechst/picoGreen ratio dsDNA spots, net 
of nuclear DNA, were revealed. From the TMRM/picoGreen overlay the overlap 
of green spots of mtDNA and mitochondria were clearly observed. 
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5.9 Metabolomics: Gas chromatography mass spectrometry (GC-MS) 
Cells were grown at standard culturing condition as described in cell culture 
methods, but with carbon-13 labelled glucose/glutamine to the media. The 
metabolomics analysis and the procedure described below, was done in 
collaboration with Dr Mariia Yuneva at the Crick Institute. 
Before metabolite extraction, cell plates were taken to a cold room 500μL of 
medium from each plate was put into 1.5mL tubes, for later analysis, and frozen. 
The remaining media was removed and the plates placed in Fan ice/water bath 
before washing two times with 5ml of ice-cold PBS. 
To extract the metabolites the following process was used: 800μL ice-cold 
methanol, containing an internal standard of 1mM scyllo-inositol, was added to 
the plates; cells were then detached from the plate by scraping with a cell 
scraper. This mixture was added to a 15ml tube, and the plate then washed with 
400μL of methanol and 400μL of H2O which was also added to the tube. Then 
400μL of ice-cold chloroform was added to each tube. The tubes were placed in a 
water bath sonicator in a cold room for one hour, with 3x8 minute pulses of 
sonication and then centrifuged for 10 minutes at 16,000rpm at a temperature 
of 0°C. The supernatant was extracted and dried in a vacuum concentrator. The 
cell pellet was then re-extracted with 200μL of methanol and 100μL of H20, this 
was sonicated, spun and the supernatant added to previous supernatant tube 
and dried again in a vacuum concentrator. The remaining cell pellet was used for 
estimating dry weight and measuring total protein. The dried supernatant was 
resuspended in 50μL chloroform, 150μL methanol and 150μL H2O and spun for 5 
minutes at 0°C and 16,000rpm. The extract is then in a biphasic partition, with 
the upper phase containing the polar metabolites and the lower phase 
containing lipidic metabolites. The polar phase portions of each extract were 
then transferred to GC-MS vial inserts and dried in a vacuum concentrator. 
Separate vial inserts had 10μL of the saved cell culture medium added, with 
1mM scyllo-inositol, which were also dried in a vacuum concentrator. Each vial 
insert then had 30μL of methanol added, containing 1μL of 5mM nor-leucine as 
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another internal standard, followed by 30μL of methanol without nor-leucine, 
with the vials being dried in a vacuum concentrator after each addition. Before 
running samples on the mass spectrometer, derivatisation was done to improve 
GC separation. 20μL methoxyamine (30mg/mL in pyridine) was added to each 
insert and this was vortexed briefly and then incubated at room temperature 
overnight, Silylation was then done by adding 20μL of BSTFA + TCMS reagent to 
each inset and incubating for 1 hour at room temperature. An Agilent 7890A GC 
with a 5975C triple axis detector MSD (Agilent Technologies, Santa Clara, CA) was 
used to analyse the samples. Metabolites were separated on an Agilent J&W 
122-5532G DB-5ms capillary column (30m x 0.25mm, 0.25um film thickness), in 
splitless mode. The injector and transfer line temperatures were 270 and 280°C, 
respectively. The flow rate of helium carrier gas was 0.7 mL/min. The oven 
temperature was programmed to hold at 70°C for 2 min, increased to 295°C at a 
12.5°C/min ramp rate, increased from 295°C to 320°C at a 25°C/min ramp rate, 
and held at 320°C for 3 minutes. The mass spectrometer was operated in scan 
mode, after a 6 minute solvent delay with a range of 50−565 mass/charge (m/z) 
and a scan-rate of 2.8 scans per second. Metabolites were identified by matching 
retention times and fragmentation patterns to commercially available standards. 
Metabolite peaks were integrated at each isotopologue m/z using MassHunter 
Workstation software (Agilent Technologies). Peak areas were quantified based 
on peak areas of known standards using nor-leucine as an internal standard, and 
then metabolite levels were normalised to protein content. Mass isotopologues 
were stripped of the contribution from natural abundance, 
based on the chemical formula of derivitised fragment quantified. Percent 
enrichment for an isotopologue was calculated by dividing the corrected 
intensity by the sum of corrected intensities of all isotopologues for that 
metabolite. Significance of metabolite enrichment between different samples 
was calculated with one-way ANOVA. 
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6. RESULTS 
 
6.1 Identification of two Mitochondrial Tumour Subtypes characterised by a 
specific nuclear encoded mitochondrial gene expression pattern 
We exploited as bioinformatics approach the MCbiclust algorithm (Bentham et 
al., 2016) to measure correlated expression. 
It was applied to the breast cancer (BRCA) microarray dataset, from the The 
Cancer Genome Atlas, for mitochondrial genes (MitoCarta, Pagliarini et al., 2008) 
in a group of cancer samples, to see whether there was a coordinated/correlated 
expression of these genes. The gene expression levels were compared one to 
each other in all the samples and a correlation value was attributed to every 
gene tested on the basis of its expression profile. High correlation was found only 
in a subset of cancer samples in which the presence of 2 highly correlated groups 
of genes emerged. The presence of two groups of nuclear encoded 
mitochondrial genes in breast cancer samples suggests the existence of a specific 
transcriptional program (Figure 6.1A). 
To confirm the hypothesised transcriptional program found by MCbiclust, in 
collaboration with Robert Bentham, PhD in Szabadkai lab in London, cancer 
samples were plotted according to the correlation strength and gene expression 
levels, using Principal Component (PC) analysis looking for the presence of 
grouped samples. Interestingly, the first hundred samples, with highly correlating 
genes, split into 2 forks. Samples belonging to the upper fork highly expressed 
gene group1 and showed low expression of gene group2; conversely, in lower 
fork samples the gene expression pattern was the opposite. On the other hand, 
samples located at the stem of the fork showed low correlation of the same 
genes (Figure 6.1B).  
The clustering of breast cancer samples, based on their mitochondrial gene 
expression profile confirmed the presence of a specific transcriptional program, 
characterised by two groups of nuclear-encoded mitochondrial genes co-
regulated in opposite way. We refer to this specific pattern as fork pattern which 
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represent a mitochondrial biogenesis pattern (Figure 6.1B-C-D). Two 
Mitochondrial Tumour Subtypes (MTSs) characterised by a specific nuclear-
encoded mitochondrial transcriptional signature, corresponding to the upper 
fork (UF) and lower fork (LF) were identified. 
The fork pattern was also partially predictive of tumour type and pathology 
currently defined and used, indeed UF samples are primarily Luminal B whereas 
LF are mainly Luminal A. Interestingly, the MTSs classification (UF and LF) did not 
show an absolute correlation with the PAM50 intrinsic subtypes of breast cancer 
samples, highlighting the potentiality of MCbiclust-based classification to 
ameliorate the metabolic stratification of breast cancer by including the aspects 
related to the nuclear-encoded mitochondrial genes through a definition of 
specific mitochondrial transcriptional signature (UF and LF). 
For this purpose it was necessary to functional verify MTSs, testing them in vitro, 
in order to identify signalling and metabolic pathways representative of the UF 
and LF. For this reason, exploiting again the MCbiclust, breast cancer cell lines 
representative of the fork pattern were selected, similarly as MCbiclust was 
applied previously to the CCLE dataset for the MitoCarta genes (Bentham et al., 
2016). 
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Table 1. Source, clinical and pathological features of tumours used to derive breast cancer cell 
lines used in this study, associated with the fork pattern. 
 
Fork 
Pattern 
Cell Line 
Gene 
cluster 
ER PR HER2 TP53 Source 
Tumour 
Type 
Age 
years 
Ethnicity 
Upper 
Fork 
(UF) 
MCF7 Lu + [+]  +/- WT PE IDC 69 W 
HCC202 Lu - [-] + [-] P.Br Duc.Ca 82 W 
MDA-MB 453 Lu - [-]  -WT PF AC 48 W 
Lower 
Fork 
(LF) 
Hs578T BaB - [-]  +M P.Br IDC 74 W 
MDA-MB 436 BaB [-] [-]  [-] PE IDC 43 W 
 
AC, adenocarcinoma; BaB, Basal B; Duc.Ca, ductal carcinoma; IDC, invasive ductal carcinoma; Lu, 
luminal; P.Br, primary breast; PE, pleural effusion; W, White. 
ER/PR/HER2/TP53 status: ER/PR positivity, HER2 overexpression, and TP53 protein levels and 
mutational status (obtained from the Sanger web site; M, mutant protein; WT, wild-type protein) 
are indicated. Expression data are derived from mRNA and protein levels. Square brackets 
indicate that levels are inferred from mRNA levels alone where protein data is not available. 
Adapted from Neve RM et al., Cancer Cell. 10: 515-27 (2006). 
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Figure 6.1 Transcriptional signature of mitochondrial biogenesis (or MCbiclust and the resulted 
Fork Pattern) A: Correlation of gene expression levels in 100 clustered samples. The gene-gene 
heatmaps of the BRCA bicluster showing the division of the genes into two groups with different 
regulation in the upper and lower fork samples. Figure produced by Robert Bentham.  B: Fork 
pattern. Ranking of the samples according to the correlation strength of gene group1 and gene 
group2. Figure produced by Gyorgy Szabadkai. C:Transcriptional program: co-regulation in 
opposite way of gene group1 and gene group2. D: Mitochondrial tumour subtypes (MTSs): 
characterised by nuclear encoded mitochondrial transcriptional signature. 
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6.2 Mitochondrial tumour subtypes differentially express respiratory chain 
complexes and this is reflected in mitochondrial function 
We decided to characterise the mitochondrial biogenesis pattern associated with 
the MTSs, upper fork and lower fork, starting from the proteins crucial for ATP 
production.  
We kept the breast cancer cell lines representative of the fork pattern (UF: 
MCF7, HCC202, MDA-MB 453; LF: Hs578T, MDA-MB 436) at standard culturing 
condition (glucose 25mM, glutamine 2mM and pyruvate 1mM). Cells were 
collected and the protein expression profile of the respiratory chain complexes 
was evaluated by western blotting analysis, using the MitoProfile antibody 
cocktail which recognises one subunit of each respiratory chain complex (CI 
subunit NDUFB8, CII-30kDa, CIII-Core protein 2, CIV subunit I, CV alpha subunit. 
The mAbs in the cocktail were chosen by the company, because they are against 
a subunit that is labile when its complex is not assembled). We interpreted the 
variation of protein expression of the single subunit as a variation of the entire 
complex. We normalised the results obtained for each subunit to β-tubulin, the 
mitochondrial heat shock protein grp75 and the glycolytic enzyme 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), to highlight differences 
related to the cytoplasm/cytoskeleton, the mitochondrial content and glycolytic 
function (Figure6.2A). Interestingly, significant differences were found in ETC 
protein expression between UF and LF; in particular looking at the normalisation 
to the general state of the mitochondria, we observed complex I and IV more 
expressed in the UF compared to the LF (Figure 6.2C-D). Moreover, we analysed 
also the ratio between the proteins on which complexes were normalised to. 
Interestingly, the grp75/β-tubulin ratio indicated that UF has more mitochondrial 
content at protein level then LF and the same result was found also for the 
glycolytic enzyme gapdh (Figure 6.2B). In summary, these results showed 
differences in expression of OXPHOS component between the two forks, in 
particular UF revealed higher mitochondrial content of CI and CIV as compared 
to the LF. 
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To verify if these differences in respiratory chain protein expression could reflect 
a different mitochondrial function between UF and LF, we followed the 
mitochondrial respiration by measuring the oxygen consumption rate with 
Oroboros assay. The experiment was done in collaboration with Cathy Qin, an 
undergraduate medical student at UCL London. The levels of oxygen consumed 
by mitochondria in order to produce ATP gave information on the working status 
of the ETC. Cells were cultured at standard culturing condition; the oxygen 
consumption was evaluated at: basal respiration, when ETC and ATP synthase 
are coupled; Leak (uncoupled) state, when ATP synthase is inhibited by 
olygomicin and the oxygen consumption is due to the proton leak through the 
inner mitochondrial membrane; maximal respiration, in which there is 
uncoupling between the ETC and ATP synthase obtained after addition of the un-
coupler FCCP and consequently protons can easily flow inside mitochondrial 
matrix dissolving the membrane potential and rendering ETC independent form 
the proton gradient.  The results (Figure 6.2E) showed higher respiration (higher 
oxygen consumption) of the UF in basal, Leak (uncoupling) and maximal 
respiration states compared to the LF and the differences were statistical 
significant. These results confirmed that the proteomic differences observed by 
western blotting analysis cause functional mitochondrial differences. 
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Figure 6.2 Expression profile of respiratory chain complexes and related function A: 
Representative western blots image. Results obtained from UF cell lines (MCF7,HCC202, MDA-
MB-453) and LF (Hs578 T, MDA-MB-436) using MitoProfile antibody cocktail to see Complex I, II, 
III, IV, V (CI,CII,CIII,CIV,CV). B: Mitochondria content: grp75/β-tubulin ratio is higher in UF.  C: 
Quantification: CI and CIV are significantly more expressed in the UF. n=3, t-test; significance with 
p-value < 0.05. D: Complexes relative changes: UF/LF ratio shows CI and CIV more expressed in 
UF compared to LF. E: Oxygen consumption rate: Differing oxygen consumption rates in the 
44 
  
cancer cell lines, B=basal rate, U=uncoupling rate and M=maximal rate. The difference between 
the upper and lower fork cell lines was found to be significant with a p-value < 0.05. 
Figure produced by Gyorgy Szabadkai. 
 
6.3 The nuclear-encoded mitochondrial expression pattern associated to 
different metabolic pathways can drive different substrate preference between 
upper fork and lower fork 
It is known that many enzymes important for the intermediate metabolism 
localise inside mitochondria; moreover, the presence of mitochondrial shuttles 
and transporters links the metabolic reactions occurring in the mitochondrion to 
which ones happening in the cytosol, highlighting the role of this organelle in 
orchestrating metabolism. Interestingly, we found a different expression profile 
of the respiratory chain complexes, between UF and LF, that could influence the 
mitochondrial oxidative metabolism and leading to specific metabolic programs 
characteristic of each fork.  
Given these premises, with the aim to understand the metabolic arrangement of 
the UF and LF, we focused our attention on global cellular metabolism using 
different approaches: protein expression analysis, bioinformatics and 
metabolomics.  
 
6.3.1 Metabolic enzymes involved in different pathways are differently 
expressed at protein level in the fork pattern 
We evaluated the protein expression level of metabolic enzymes belonging to 
different pathways of energetic and intermediate metabolism: glycolysis (HK1, 
HK2, TPI, PKM1, PKM2); TCA cycle (PDH-E1a, IDH, IDH2), malate shuttle and 
pyruvate metabolism (ME1, ME2, ME3), purine pyrimidine biosynthesis (PPAT), 
serine metabolism (PHGDH, PSAT1), glutamine/glutamate metabolism (GLS1, 
GLUD, GOT1, GS), hexosamine pathway (GFPT1, GFPT2) (Table2). It is known that 
some enzymes preferentially use glucose-derived substrates, others glutamine-
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derived substrate, others exploit the pyruvate produced inside the cell favouring 
pyruvate anaplerosis.  
The possible differences in protein expression existing between the two forks, 
could predict which pathway is preferentially used by the two MTSs to sustain  
the metabolic needs of the cells and indicate which substrate could be better 
utilised to sustain cell viability and functionality. We evaluated the protein 
expression in breast cancer cell lines representative of the fork pattern by 
western blotting (Figure 6.3.1A). For normalisation we referred to the 
housekeeping protein α-actin and the mitochondrial heat shock protein grp75. 
The expression profile of each cell line and the results grouped for UF and LF 
were evaluated. For some enzymes the expression pattern of cells belonging to 
the same fork was identical, making the differences in the grouped results 
statistically significant, highlighting metabolic features of the forks. In other 
cases, the differences among the cell lines belonging to the same fork did not 
give significance to the grouped outcomes.  
Starting the analysis from the housekeeping proteins, the grp75/α-actin ratio 
showed that UF cells had more grp75 then LF (Figure 6.3.1B); the difference was 
statistically significant, indicating a status in which UF generally has higher 
mitochondrial content compared with LF (Figure 6.3.1B); this is in agreement 
with the result emerged from grp75/β-tubulin ratio showed in the previous 
paragraph (Figure 6.2B). Successively, going through the results of metabolic 
enzymes, we found differences in protein expression between UF and LF, which 
were statistically significant. In particular, two enzymes, GLUD and GLS1, 
involved in the glutamine/glutamate metabolism and both localising at 
mitochondrial level, were expressed in opposite way in the two forks; GLUD that 
catalyses the oxidative deamination of glutamate to alpha-ketoglutarate and   
ammonia showed increased expression in the UF, whereas  GLS1 that hydrolyses 
glutamine to glutamate and ammonia was more expressed in the LF (Figure 
6.3.1C). Interestingly, these two enzymes characterised by the opposite 
expression in the two forks, share the substrate/product glutamate (Figure 
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6.3.1D) indicating that glutamine/glutamate metabolism could be differently 
arranged between MTSs. Others enzymes, GOT1 and GS, belonging to the same 
metabolic pathway were tested, but no significant differences has emerged 
(Figure 6.3.1C).  
Next, we focused on other pathways in which glutamine and glutamate were 
involved as reactive substrates. In the purine/pyrimidine biosynthesis the 
enzyme PPAT, which uses glutamate to convert the 5-phosphoribosylamine-
diphosphate in 5-phosphoribose-1-diphosphate and glutamine in the first step of 
the pathway, did not shown differences between UF and LF at grouped level, 
probably because of the variability in protein expression between the two LF cell 
lines (Figure 6.3.1E). We evaluated also pathways in which glucose and glutamine 
metabolism are linked: serine metabolism and the hexosamine pathway. In 
serine metabolism two enzymes were tested; from the comparison of the 
grouped results between UF and LF, we found significant differences in the 
protein expression of the enzyme PSAT1 (Figure 6.3.1F). The enzyme, which 
catalyses the reaction between phospho-serine (or phospho-threonine) and α-
ketoglutarate to produce 3-phospho-pyruvate (or phosphor-butanoate) and 
glutamate, was more expressed in the LF and this profile was confirmed also 
looking at the level of the single cell line. Instead, we did not find differences for 
the enzyme PHGDH, which converts the 3-phospho-glycerate into 3-phospho 
oxypyruvate with a reduction of NAD+ to NADH, between UF and LF at grouped 
level; however, looking at the protein expression of each cell lines, we observed 
variability among cells of the UF (Figure 6.3.1F). For the hexosamine pathway, we 
tested two enzymes GFPT1 and GFPT2, which both control the glucose flux into 
the pathway. In particular, the reaction involves D-fructose-6-phosphate (a 
glucose-derived substrate) and glutamine which are converted into D-
glucosamine-6-phosphate and glutamate. We found a specific pattern for GFPT2 
which was highly expressed in the LF, both looking at the single cell line 
expression and the grouped results, which were statistical significant (Figure 
6.3.1G). 
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Next, enzymes involved in glucose metabolism were also analysed, in order to 
evaluate if the MTSs could different exploit the glucose substrate. Concerning 
the glycolysis, we measured the expression of HK1 and HK2 proteins, the last one 
is the isoform usually associated with cancer; moreover, both enzymes catalyse 
glucose phosphorylation to produce glucose-6-phosphate. We found no 
differences between MTSs in HK1 and HK2 expression (Figure 6.3.1H). We 
analysed also TPI, which catalyses the isomerization of glyceraldehydes 3-
phosphate (G3P) and dihydroxy-acetone phosphate (DHAP). When we looked at 
the protein expression individually of the cell lines, we found variability in the UF, 
in particular HCC202 cell line expressed less enzyme compared to the other two 
UF cell types. However, when we observed the grouped results, TPI was 
significantly more expressed in the LF, but only when the normalisation was 
done to the mitochondrial protein grp75 (Figure 6.3.1H); the content of this 
glycolytic enzyme is higher in LF only related to the mitochondrial content, 
indicating again that LF has less mitochondria then UF. The last glycolytic 
enzymes we evaluated were PKM1 and PKM2; both enzymes catalyse the 
transfer of a phosphoryl group from phosphoenolpyruvate to ADP, generating 
ATP and pyruvate. PKM2 isoform, usually associated to cancer metabolism (ref), 
did not show differences between UF and LF. However there was variability in 
the UF cell lines (Figure 6.3.1H). Surprisingly, we found PKM1 significantly more 
expressed in LF, looking at the expression of both single cell lines and grouped 
results (Figure 6.3.1H).  
Pyruvate is the end product derived from glycolysis, and it can undergo three 
different fates: it can be transported into mitochondria through the 
mitochondrial pyruvate carrier and fuel the TCA cycle or converted into lactate 
by the action of lactate dehydrogenase, or it can be carboxylated by pyruvate 
carboxylase to produce oxaloacetate favouring mitochondrial anaplerosis. Here, 
the route of the TCA cycle was considered. PDH-E1α, IDH1 and IDH2 protein 
expression was measured. PDH-E1 is part of the pyruvate dehydrogenase 
complex (PDC), a nuclear-encoded mitochondrial multi-enzyme complex that 
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catalyses the oxidative decarboxylation of pyruvate to acetyl-CoA and CO2, 
providing the primary link between glycolysis and TCA cycle. PDH-E1α is a 
subunit of the pyruvate dehydrogenase enzyme (PDH-E1), a hetero-tetramer of 
two alpha and two beta subunits. We found no significant difference in protein 
expression between UF and LF (Figure 6.3.1I); however the enzymatic activity is 
controlled by phosphorylating-(inactivation)/dephosphorylating-(activation) 
events to work of PDKs (pyruvate dehydrogenase kinases) and PDPs (pyruvate 
dehydrogenase phosphate phosphatase) on PDH-E1α specific serine residues, 
meaning that despite of the PDH-E1α subunit was equally expressed on both 
forks, we do not know if there was differences in its activity. Further analysis 
need to be done to clarify this question. The enzyme IDH2 is a mitochondrial 
protein which acts in the TCA cycle catalysing the oxidative decarboxylation of 
isocitrate to α-ketoglutarte; IDH1 is the cytosolic counterpart that promotes the 
same reaction in the cytoplasm, for this reason we treated IDH1 in this section. 
We found both enzymes more expressed in the UF when they were normalised 
to α-actin (Figure 6.3.1I). Finally, we analysed enzymes involved in the malate 
shuttle and pyruvate metabolism. Three isoforms of malic enzymes (MEs) are 
known, all of them catalysing the oxidative decarboxylation of malate in the 
presence of NAD(P)+ and the decarboxylation of oxaloacetate. The ME1 is 
the cytosolic isoform NADP-dependent, ME2 NAD-dependent and ME3 NADP-
dependent isoforms localise both in the mitochondria. We found no differences 
in ME1 expression between UF and LF (Figure 6.3.1L); whereas for the ME2 and 
ME3 we have some preliminary results (data not shown), but more experiments 
need to be done in order to obtain conclusive data.  
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Table 2. Pathway, enzyme acronym and full name, reaction and localisation. 
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Figure 6.3.1 Different protein expression profile of metabolic enzymes between UF and LF in 
breast cancer cell lines A: Representative western blots image and mitochondrial content: the 
protein expression of metabolic enzymes belonging to different pathways were evaluated in UF 
and LF breast cancer cell lines. B: Mitochondria content: grp75/α-actin ratio is higher in UF; n=3; 
t-test with a significance ***<0.0001. C: Glutamine/glutamate metabolism: quantification; n=3; t-
test with a significance *p-value <0.05; ** p-value <0.01; ***p-value < 0.0001. D: Kegg scheme of 
glutamine and glutamate metabolism: GLS1 and GLUD were highlighted according to the fork 
pattern; glutamate is the common substrate/product shared by the two enzymes. E: 
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Purine/pyrimidine biosynthesis: quantification; n=3. F: Serine metabolism: quantification; n=3; t-
test with a significance *p-value <0.05; ** p-value <0.01.    G: Hexosamine pathway: 
quantification; n=3; t-test with a significance ** p-value <0.01. H: Glycolysis: quantification; n=3; 
t-test with a significance ** p-value <0.01; *** p-value <0.0001. I: TCA cycle: quantification; n=3; 
t-test with a significance *p-value <0.05; ** p-value <0.01. L: Malate shuttle and pyruvate 
metabolism: quantification; n=3. “red colour: Upper Fork; blue colour: Lower Fork”. 
 
6.3.2 Correlation between metabolic gene expression levels and the fork 
pattern 
The differences we found in the protein expression profile of metabolic enzymes 
in breast cancer cell lines representative of the fork pattern suggested that the 
MTSs might have a different arrangement of the metabolic pathways through 
which the substrates glucose and glutamine are metabolised. Indeed, the results 
obtained so far by western blotting analysis seem to suggest that LF is more 
prone to use reactions in which glutamine and glutamine-derived substrates are 
involved. 
To see whether these observations were confirmed also in breast cancer 
samples, we looked for the correlation between metabolic gene expression 
levels and the fork pattern in transcriptomics data in breast tumour samples; the 
correlation values of mRNA expression ranged from -1 to +1: positive values, 
indicating a positive correlation, were associated with the UF, whereas negative 
values (negative correlation) were related to the LF. By exploiting the 
transcriptional data available and Kyoto encyclopedia of genes and genomes 
(Kegg) database, we attributed a correlation value to the metabolic enzymes 
belonging to glycolysis, TCA cycle and pyruvate/acetyl-CoA metabolism. We 
found that metabolic enzymes differently correlated with the fork pattern in 
breast cancer samples at gene expression level; in particular in the glycolysis 
most enzymes had positive correlation indicating they were more expressed in 
the UF (Figure 6.3.2A); in the TCA cycle (Figure 6.3.2B) and in the 
pyruvate/acetyl-CoA metabolism (Figure 6.3.2C) we observed different parts of 
both pathways correlating with UF whereas other parts with LF, indicating that 
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some enzymes were more expressed in the UF and others in the LF. Moreover, 
based on the results obtained by western blotting analysis, that highlighted 
differences in protein expression of GLS1 and GLUD enzymes between UF and LF 
in breast cancer cell lines, we looked also at the glutamine/glutamate 
metabolism. Again, we observed that some enzymes of the pathway correlated 
more with the UF and other with the LF (Figure 6.3.2D). Interestingly, the results 
for GFPT2 was confirmed, it was more expressed in the LF at transcriptional level 
of breast cancer samples as well, perfectly in agreement with the western 
blotting data; however for the enzyme GLUD we found the opposite behaviour 
compared to the proteomic analysis, indeed in this correlation experiment GLUD 
was associated with the LF and not with UF.  
Overall, these correlation results obtained from gene expression data originated 
from breast cancer samples, confirmed the indication we already found at 
protein level obtained from breast cancer cell lines: the differences at genes 
expression level of metabolic enzymes in the fork pattern suggest which pathway 
is preferentially used by each fork or, more precisely, which is the enzymatic 
arrangement of a specific pathway that confer the best yield to that pathway and 
thus might predict the substrate, glucose or glutamine, that are better exploit by 
UF or LF. 
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Figure 6.3.2 Different metabolic arrangement between UF and LF at gene expression level in 
breast cancer samples A: Glycolysis. B: TCA cycle. C: Pyruvate/acetyl CoA metabolism. D: 
Glutamine/glutamate metabolism. 
“Metabolic schemes are taken from Kegg; red colour is associated with Upper Fork and blue with 
Lower Fork; the red box includes the acronymus of the enzymes flanked by the correlation 
value”. 
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6.3.3 Metabolomics 
In the analysis done until now to understand the metabolic arrangement of the 
UF and LF, both the approaches we used (proteomic and transcriptomic analysis 
respectively on breast cancer cell lines and breast cancer samples) indicated that 
the two mitochondrial tumour subtypes differently utilise metabolic pathways. 
To verify if these results could reflect different overall metabolic flow of 
mitochondrial cancer subtypes, in collaboration with Dr. Mariia Yuneva of the 
Crick Institute, metabolomics and flux analysis of the representative breast 
cancer cell lines was performed. Cells were treated with medium containing 
labelled 13-carbon glucose, 13-carbon glutamine or 13-carbon pyruvate and the 
derived metabolites were analysed using the gas-chromatography mass 
spectrometry. If glucose utilisation in the TCA cycle is considered, one round of 
the cycle produces two labelled carbon (M+2) atoms for each TCA cycle 
intermediates, instead glutamine utilisation produces metabolites with four 
labelled carbons (M+4) (Figure 6.3.3A). It is of note that more rounds of the cycle 
usually occur producing isotopologues with one (M+1), three (M+3), five (M+5) 
labelled carbons; moreover the cycle instead of developing in the canonical 
oxidative direction can turn back in the reductive mode, but these scenarios 
were not considered in text. Indeed, further analysis are still in progress to better 
elucidate all the possible pathways. 
We tried to understand the efficiency of glucose and glutamine utilisation in the 
TCA cycle analysing the cell lines representative of the fork pattern. The nutrient 
concentration of the experimental media, prepared with 13-carbon labelled 
substrates, was glucose 10mM and glutamine 1mM, supplemented or not with 
pyruvate (HH+, HH-). The overall incorporation of labelled carbons highlighted 
that UF incorporated more labelled carbons from glucose than LF, while LF 
generally incorporated more labelled carbons from glutamine then UF. 
Moreover, LF incorporates labelled carbon from pyruvate more than UF (Figure 
6.3.3B). Next, we focused on the fractional enrichment of some labelled 
metabolites alanine and malate. The graph of alanine relative incorporation 
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showed that the alanine labelling derives almost completely from pyruvate-
derived glucose for both UF and LF, however looking at the fractional enrichment 
we observed that UF produces more alanine derived from glucose compared to 
the LF (Figure 6.3.3C). On the other hand, the graph of malate relative 
incorporation showed the usage of both glucose (M+2, M+3) and glutamine 
(M+4) to produce malate. Moreover, we observed also that the majority of 
labelled-malate derives from glutamine and even if UF had more malate and the 
isotopologue M+4 was comparable between the two forks, the fractional 
enrichment showed that the labelling from glutamine was higher in the LF 
(Figure 6.3.3D). In summary, we observed that upper fork cells use more 
efficiently glucose whereas lower fork cells prefer glutamine as carbon source in 
the TCA cycle. This is in agreement with the results obtained so far, indicating 
that the differences in the enzymatic arrangement could determine a substrate 
preference. 
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Fig.6.3.3 Substrate preference observed by gas chromatography mass spectrometry A: Flux  
scheme: the picture represents the TCA cycle, fuelled by the glucose derived-pyruvate and 
glutamine. Each circle correspond to a carbon atom that can be labelled or not (white circle). Rad 
colour is the labelling derived from glucose which produces isotopologue substrates M+2, 
whereas the blue colour represents the labelling obtained from glutamine and the isotopologues 
are M+4. B: Overall incorporation of labelled carbons: the labelling derived from glucose is higher 
in the UF, the labelling derived from glutamine is higher in the LF. C: Alanine relative 
incorporation and fractional enrichment: the graphs show the usage of glucose-derived pyruvate 
more efficiently in the UF to produce alanine.  D: Malate relative incorporation and fractional 
enrichment: malate is labelled from both glucose and glutamine. The labelling from glutamine is 
more efficient in  the LF compared to the UF. 
 
6.4 Deprivation effect: acute response and adaptation 
The results obtained so far have indicated a different mitochondrial biogenesis 
pattern associate to UF and LF; this was highlighted by the protein expression 
profile of the respiratory chain complexes, indeed CI and CIV were increased in 
the UF, causing a different function in terms of oxygen consumption between the 
forks; moreover the differences in expression of metabolic enzymes, at both 
transcriptional and proteome level, and the nutrients utilisation by the fork 
pattern assessed by metabolomics, suggested that MTSs may diversely exploit 
metabolic pathways to adopt to a variable nutrients availability. 
Our results, indicating that the mitochondrial tumour subtypes (UF and LF) we 
identified have different substrate preferences and since nutrients supply of 
cancer cells in vivo can vary and consequently tumours evolve in order to adapt 
to the microenvironment, we decided to test the sensitivity of the representative 
breast cancer cell lines to deprivation of different nutrients. For this reason, we 
reduced either glucose or glutamine concentration. Moreover, we tested 
whether the primary TCA cycle substrate pyruvate has any effect. We evaluated 
the contribution of these nutrients to different aspect of cell viability: cell 
growth, metabolic changes (ATP production, mitochondrial membrane 
potential), adaptive mitochondrial biogenesis (mitochondrial protein expression 
and mtDNA content). 
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6.4.1 Cell growth depend on the presence of glucose and glutamine 
With the purpose to evaluate the efficiency to utilise substrates for the 
biosynthesis, we started to set up a protocol of proliferation assay to measure 
the cell growth at different nutrients availability. Initially we followed the cell 
growth in a time course of 19 days: at day 1 cells were seeded, at day 4 the 
experimental medium was added and finally cells were counted 3 times at day 6, 
12 and 19. As first step, we tested the glucose contribution to the cell growth 
giving to the cells media with different glucose concentration (high 10mM or low 
0.75mM) or galactose (10mM) instead of glucose, supplied with or without 
pyruvate (1mM). After counting, the doubling time (dt) and a ratio high/low dt, 
high/gal dt were calculated. We obtained some preliminary results which 
showed a general slowing down of the doubling time of both forks cell lines in 
low glucose and in galactose condition; nevertheless the high/low dt ratios 
indicated that cells were able to survive in condition of glucose deprivation 
suggesting an adaptation.  
We invested around six months in the setting-up of the protocol, but despite of 
the promising results, the method had many technical problems; indeed to build 
comparable growth curves it was necessary to seed the same cell number for all 
the cell lines, but the intrinsic features of some lines made them sensitive to the 
cell dilution, so in some experiments we didn’t obtain results for some of the cell 
lines tested, moreover the variability was high. Furthermore, for each 
experiment the protocol and the analysis required almost one month. For these 
reasons, we moved to another approach. 
We decided to evaluate cell proliferation by imaging, in a time course of 8 days, 
testing the sensitivity of the cells to the combination of reduced glucose or 
glutamine concentration, in presence or absence of pyruvate. We observed that 
glucose-deprived cells did not growth despite of the presence of glutamine 
(Figure 6.4.1 A-B: green trace), indicating that both forks rely on aerobic 
glycolysis; moreover cell proliferation slowed down consequently of glutamine 
reduction as well even if glucose was still in the medium (Figure 6.4.1 A-B: red 
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trace); interestingly, we also observed that if pyruvate was present, cell growth 
was rescued in the UF but not in the LF (Figure 6.4.1 A-B: red trace), showing that 
these two substrate, pyruvate and glutamine, have a different impact of the 
forks. In conclusion, not surprisingly we found that proliferation of cells from 
both groups was dependent on the presence of high glucose in the medium, 
showing that both cell types use aerobic glycolysis for biosynthesis (Figure 6.4.1 
A-B). We also observed that glutamine as well influence the cell growth, but 
interestingly the presence of this substrate was more important for LF. 
Moreover, in situation of glutamine deprivation, only UF was able to exploit 
pyruvate to sustain the cell growth. 
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Figure 6.4.1 Cell growth depends on glucose and glutamine A: Cell growth imaging of the upper 
fork. B: Cell growth imaging of the lower fork. “HH: high glucose, high glutamine (black trace); 
HL: high glucose, low glutamine (red trace); LH: low glucose, high glutamine (green trace); LL: low 
glucose, low glutamine (yellow trace). Glucose: high correspond to 25mM and low to 0.75mM. 
Glutamine: high correspond to 2mM and low to 0.2mM”. 
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6.4.2 The ATP production and the mitochondrial membrane potential are 
influenced by substrate preferences  
Mitochondria are sensors of cell health, consequently parameters like 
mitochondrial membrane potential (Δψm) and ATP production give information 
about the general status of the cell. For this reason, we evaluated these two 
parameters in our cellular models representative of the fork pattern.  
We measured the ATP levels after 30 minutes and 24 hours of deprivation, to 
assess the energy production during the acute response and the adaptation. To 
discriminate the contribution of mitochondria and glycolysis to this process, we 
treated cells with oligomycin (ATP synthase inhibitor) or 2-deoxiglucose (glucose 
analogue which is not processed through glycolysis). The glycolytic ATP pattern 
at 30’ and 24h of deprivation was essentially the same found for the amount of 
total ATP (Figure 6.4.2 A-B); the contribution of mitochondria to the ATP 
production appears very limited (Figure 6.4.2 C), indicating that both UF and LF 
cells are primarily glycolytic, limiting the energy production to this pathway, 
suggesting also that the major role of mitochondria is to supply metabolic 
intermediates. Moreover, the two forks used different substrates for the ATP 
production: when glutamine was reduced (HL-/+) the ATP production of LF 
decreased (Figure 6.4.2 A-B), indicating that LF is sensitive to glutamine 
deprivation independently from the presence of glucose; interestingly, pyruvate 
increased the ATP production only in the UF during the acute response (30min) 
(Figure 6.4.2 A-B). 
The second aspect of mitochondrial health we evaluated is the steady-state 
mitochondrial membrane potential Δψm, which was measured using the cationic 
fluorescent dye TMRM. The status of Δψm give information on the OXPHOS 
activity and the contribution of mitochondria to the cell proliferation process. For 
this part, cells were cultured with media containing reduced concentration of 
either glucose or glutamine, in presence or absence of pyruvate; then Δψm was 
recorded by imaging. We observed a striking difference between the MTSs. UF 
cells depolarised in the absence of glucose, while LF cells were able to maintain a 
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membrane potential. On the other hand, in glutamine deprivation UF 
depolarised despite of the presence of pyruvate, whereas LF did not. This 
confirms that upper fork relies on glucose for the mitochondrial activity, whereas 
lower fork cells utilise other substrates than glucose derived pyruvate, such as 
glutamine present in the medium, more efficiently to feed into the TCA cycle and 
provide electrons for maintaining OXPHOS activity. Moreover, in LF pyruvate 
preserved the Δψm in glutamine deprivation, but it wasn’t able to rescue the cell 
growth in the same type of cell, recovery that was done in the UF, meaning that 
pyruvate acts at different levels in the MTSs. 
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Figure 6.4.2 Mitochondrial physiology status. 
Energy production: glycolysis versus mitochondria A: Total ATP: produced after 30’ and 24h of 
deprivation.  B: Glycolytic ATP: produced after 30’ and 24h of deprivation, showing a similar 
pattern of the total ATP. C: Mitochondrial ATP: produced after 30’ and 24h of deprivation, 
showing a minimal contribution of mitochondria to the ATP production. D: Method: Total 
represents ATP values produced by cells not treated with inhibitors. Oligo indicates ATP recorded 
after oligomycin treatment (ATP synthase inhibitor), meaning that glycolysis is the main source of 
ATP. 2-DG corresponds to the ATP produced after glycolysis inhibition, so the ATP is 
mitochondrial-derived. Total, Oligo and 2-DG data comprise the background. Data analysis: the 
mitochondrial ATP and glycolytic ATP, net of the background, were calculated subtracting 
respectively  Oligo and 2-DG to the Total values. The total ATP produced, not comprising the 
background, was determined as the sum of glycolytic ATP and mitochondrial ATP in absolute 
values. “black: HH -pyr; gray: HH +pyr; dark red: HL -pyr; light red: HL +pyr; dark green: LH -pyr; 
light green: LH +pyr; dark yellow: LL -pyr; light yellow: LL +pyr.  HH: high glucose, high glutamine; 
HL: high glucose, low glutamine; LH: low glucose, high glutamine; LL: low glucose, low glutamine. 
Pyruvate supplementation: +pyr (1mM) ,  -pyr (0mM). Glucose: high correspond to 25mM and 
low to 0.75mM. Glutamine: high correspond to 2mM and low to 0.2mM. Oligo = oligomycin; 2-
DG= 2-deoxyglucose” 
Mitochondrial membrane potential E: Steady state mitochondrial membrane potential (Δψm): 
plots produced by Gyorgy Szabadkai. 
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6.4.3 Different mitochondrial biogenesis programs provide adaptation to 
different nutrient supply  
The results emerged from imaging the cell growth during deprivation of different 
nutrients, highlighted the importance of glucose for cell proliferation for both 
type of cells, indeed both UF and LF exploit glucose and aerobic glycolysis for 
biosynthesis. To further understand how cells adapt to the lack of glucose, we 
measured the expression of OXPHOS components under conditions of glucose 
deprivation. Cells were seeded at day 1, the experimental medium was added at 
day 4 and cells let grow until day 19. The protein expression profile of the 
respiratory chain complexes was evaluated by western blotting analysis and the 
results normalised to β-tubulin, grp75 and gapdh. To better visualise the 
deprivation effect, we normalised the obtained data to the control condition 
(glucose 25mM and glutamine 2mM). The two forks differently adopted to 
glucose deprivation, we found UF with increased Complex I (CI) expression, but 
looking at the normalisation to mitochondria content and gapdh there was no 
increase or a slight increase. On the other hand, LF increased the CI expression 
looking at all the normalisation done (Figure 6.4.3A). Similar results were 
obtained in presence and absence of pyruvate (Figure6.4.3A-B). Summarising, 
upper fork co-regulates respiratory complexes and GAPDH, lower fork induces 
the expression selectively of the respiratory complexes. 
Since the glucose deprivation treatment have induced the adaptive expression of 
respiratory chain complexes in both cell types, suggesting that mitochondrial 
biogenesis process was turn on, we decided to monitor the mitochondrial DNA 
(mtDNA) content in condition of nutrients deprivation. For this purpose we 
applied the same culturing protocol used for the mitochondrial membrane 
potential measurement. We observed an increase of the mtDNA content 
consequent to the deprivation treatment in both UF and LF in every deprivation 
conditions tested, indicating the activation of the mitochondrial biogenesis 
process (Figure 6.4.3B). Moreover, looking at the results normalised to the 
control condition (HH+), we observed that the response to the reduction of 
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nutrients availability was higher in LF cells (Figure 6.4.3C), suggesting that these 
cells need to increase more the mitochondrial content then UF, which we 
observed to already have an higher mitochondrial content in basal condition 
(Figure 6.2B, 6.3.1B). 
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Figure 6.4.3 Adaptive mitochondrial biogenesis A: Complex I induction after glucose deprivation, 
in presence of pyruvate. B: Complex I induction after glucose deprivation, in absence of pyruvate. 
C: Increased mitochondrial DNA content: deprivation treatment induced mitochondrial 
biogenesis. D: Mitochondrial DNA content relative changes: the increase of mtDNA content is 
higher in LF.  
Plots in  C and D were produced by Gyorgy Szabadkai. 
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7. DISCUSSION 
 
Tumours are currently defined by the hallmarks of cancer, which comprise the 
capabilities that enable tumour growth and metastatic dissemination (Hanahan 
D et al., 2000). It is of note that virtually all the hallmarks are linked to tumour 
metabolism, indeed the conceptual progress in the last decades suggests that 
two new hallmarks are involved in the pathogenesis of the majority of cancers: 
reprogramming of energy metabolism (Kroemer G et al., 2008; Hanahan D et al., 
2011) and evading immune destruction (Hanahan D et al., 2011). We decided to 
address the reprogramming of cellular metabolism and bioenergetics in breast 
cancer model. 
Breast cancer is one of the most common forms of cancer in women worldwide.  
It is a heterogeneous disease with various molecular alterations, cellular 
composition, and clinical outcome. It is defined by clinical and pathological 
features, histochemical markers (ER, PR, Her2) and diverse oncogenic 
transcriptional programs that led to a definition of the subtypes currently used in 
clinical studies to define the best treatment options: basal-like, Her2-enriched, 
Luminal A, Luminal B and normal-like. Importantly, so far none of the 
classification methods have taken into consideration the metabolic phenotype 
and gene expression pattern of these tumours.  
In this work we define for the first time Mitochondrial Tumour Subtypes (MTSs), 
moreover, we provide their characterisation looking at the link between specific 
mitochondrial biogenesis patterns a and specific bioenergetics and metabolic 
phenotype. 
The MTSs was found thanks to the development of a novel algorithm MCbiclust 
done by our collaborator Robert Bentham. Its application to breast cancer 
transcriptional data has provided a new classification system based on nuclear-
encoded mitochondrial genes for breast cancer, where two Mitochondrial 
Tumour Subtypes (MTSs), upper fork (UF) and lower fork (LF) have been 
identified. Each MTS is characterised by two groups of mitochondrial genes co-
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regulated in opposite ways. The classification we propose offers a new insight on 
the classical features which are commonly used by clinical scientists in the 
codification of breast cancer subtypes, thanks to the inclusion of the 
mitochondrial genes of which expression can underline different programs of 
mitochondrial biogenesis. Consequently, breast tumours can be classified 
according to their mitochondrial status. The new classification and the possible 
implications are promising. For this reason, breast cancer cell lines 
representative of the fork pattern were selected, by exploiting again the 
MCbiclust algorithm, and tested in vitro.  
The upper fork cells MCF7, HCC202, MDA-MB-453 and the lower fork cells 
Hs578T, MDA-MB-436, characterised by a specific nuclear-encoded 
mitochondrial transcriptional signature, were used in this study.  
Mitochondria are key metabolic organelles, important for ATP production, 
intermediary metabolic processes, controlling the redox state of the cell and 
other fundamental signalling pathways, revealing its crucial role in cell viability, 
hence it can control adaptive responses under limiting conditions. According to 
our hypothesis, mitochondria act as a hub of metabolic remodelling organelles 
favouring tumour adaptation and evolution. We provided the first experimental 
characterisation of mitochondrial tumour subtypes UF and LF in terms of 
bioenergetics and metabolism as the aim of the work.  
The bioenergetics was evaluated at protein level and through functional assays. 
The western blotting analysis, focusing on mitochondrial respiratory chain 
proteins important for ATP production, revealed that UF subtype cells express 
more Complex I and Complex IV then cells belonging to the LF subtype. 
Moreover, UF cells generally have higher mitochondrial content compared to the 
LF, as highlighted by the ratio between the mitochondrial scaffold protein grp75 
and housekeeping proteins β-tubulin and α-actin. Interestingly, this expression 
pattern reflects differences in mitochondrial function between the two subtypes, 
rendering the UF more oxidative, evidenced by the Oroboros assay showing 
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higher oxygen consumption rate in UF cells. These evidences gave information 
on the general status of the MTSs mitochondria at basal condition. 
The metabolic profile of UF and LF was analysed in terms of expression of 
metabolic enzymes belonging to different pathways at both protein and mRNA 
level, respectively in breast cancer cell lines and breast cancer samples. Since the 
intermediary metabolism, in which mitochondria are involved, relies on the 
cross-talk between cytoplasmic and mitochondrial metabolites according to the 
well-established metabolic fluxes, the enzymes tested localise at both cytoplasm 
and mitochondria.  
We found metabolic enzymes differently expressed at protein level between the 
forks in cell line models, while from transcriptomic analysis of breast cancer 
samples (TCGA) we observed mRNA levels of metabolic enzymes differently 
correlating with the fork pattern. Both approaches indicated that UF and LF 
display a different enzymatic arrangement. In particular, UF expresses more 
enzymes of which the substrates are glucose derived, as shown by the 
correlation pattern of glycolysis (Figure 6.3.2A) and the expression of IDH1 and 
IDH2 enzymes. Importantly, these results were confirmed also by metabolomics 
that highlighted a more efficient glucose-utilisation as mitochondrial substrate 
for the TCA cycle (Figures 6.3.3B-C), since the overall incorporation of glucose-
derived labelled carbons was higher in UF. On the other hand, LF expresses more 
enzymes of which substrates are glutamine derived. Interestingly, detailed 
analysis showed significant differences for proteins involved in the 
glutamine/glutamate metabolism. After its transport into mitochondria, 
glutamine is subsequently converted by mitochondrial glutaminase (GLS1) to 
glutamate and ammonium ion, then glutamate is further catabolised to α-
ketoglutarate through two different pathways involving glutamate 
dehydrogenases and the consequent production of ammonia (GLUD) and 
glutamate aminotransferases (GOT1, GOT2, PSAT1, GPT1 and GPT2), as recently 
reviewed by Altam et al.,2016. Interestingly, GLS1 was showed higher expression 
in the LF at both protein and transcriptional levels, indicating major glutamine 
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flux in the LF mitochondrial tumour subtype. Again, these results were further 
confirmed at the functional level by metabolomics flux analysis. Indeed, both the 
overall incorporation of labelled carbon from glutamine and specific glutamine-
derived labelling of malate was higher in the LF indicating a more efficient 
glutamine utilisation in the TCA cycle by this fork (paragraph 6.3.3). The result for 
GLS1 are promising, indeed it has been reported that GLS1 upregulation is 
induced by c-Myc in cancer (Gao P et al., 2009) and its pharmacological inhibition 
suppresses tumour growth in various mouse models of cancer (Xiang Y et al., 
2015). GLS1 might be a putative target for LF subtype. 
Next, we followed the fate of glutamate. Looking at the glutamate 
dehydrogenase GLUD, we found this enzyme more expressed in the UF at 
protein level, even if the transcriptional data revealed the contrary. This opposite 
pattern for GLUD can be explained because of the two different approaches we 
used was applied to different specimens, the transcriptional data came from 
breast cancer samples derived from patients, however the proteomic results was 
obtained from breast cancer cell lines. Next, we focused on the expression 
aminotransferases protein. The phosphoserine aminotransferase (PSAT1) as a 
part of serine biosynthesis, was more expressed at protein level in the LF, 
indicating the usage of glutamine for biosynthesis. The aspartate 
aminotransferase GOT1 (cytoplasmic isoform) we analysed didn’t show 
differences between the forks. The mitochondrial counterpart will have to be 
evaluated in follow up studies together with the cytoplasmic (GPT) and 
mitochondrial (GPT2) alanine aminotransferases in order to better elucidate the 
biosynthetic role of glutamine in our models. In addition, glutamine can be used 
in the hexosamine biosynthetic pathway, which couples glucose and glutamine 
metabolism (Wellen, K et al., 2010). This pathway leads to the production of 
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), required for 
glycosylation processes. Interestingly, the rate-limiting enzyme of this pathway 
GFPT2 was strikingly more expressed in the LF. This is an intriguing result, 
indeed, the produced UDP-GlcNAc can serve as a nutrient signal reflecting 
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cellular metabolic state. Wellen, K et al., 2010 have shown that glucose flux 
through the hexosamine biosynthesis pathway regulates growth factor receptor 
glycosylation and enables glutamine consumption and hence defining a novel 
mechanism through which cellular metabolism regulates signal transduction 
through metabolic regulation of glycosylation. 
Another enzyme, significantly more expressed in the LF is the glycolytic enzyme 
PKM1 which promotes oxidative phosphorylation, that paradoxically is the PK 
isoform usually expressed in normal tissue. Indeed, the isoform normally 
associated with cancer is PKM2. However, it has been reported in literature that 
PKM1 was commonly up-regulated in various chemoresistent cells, among which 
colorectal cancers (CCC) resistant to 5-FU treatment (Taniguchi K et al., 2016; 
Denise C et al., 2015), hence PKM1 provide an advantage in CCC. However we 
still do not have an explanation of which is its role in LF mitochondrial breast 
cancer subtype, but prospectively given the possible implications in clinic, further 
investigation focused on understanding of the PKM1 upregulation in LF have to 
be done.  
Globally, the results we obtained so far suggest that LF better exploits glutamine 
thanks to a specific enzymatic arrangement, whereas the UF asset of enzymes 
confers a better glucose utilisation by this subtype. However, it is important to 
take into account that the expression of enzymes is not the only factor that 
determine the metabolic fluxes in the cell. Moreover, these results were 
obtained in basal conditions in which nutrients were not limiting, so further 
analysis to examine in depth the metabolic behaviour of MTSs should be done in 
deprivation system, evaluating how enzymatic expression can vary and what are 
the possible implications on nutrient utilisation. 
In this study, the deprivation approach was applied to MTSs with the aim to 
understand how UF and LF adapt to variable nutrient availability in the light of 
the results obtained so far: UF and LF are associated with a different 
mitochondrial biogenesis pattern characterised by a different enzymatic 
arrangement and nutrient utilisation; then, cell growth, metabolic changes (ATP 
78 
  
production, mitochondrial membrane potential) and adaptive mitochondrial 
biogenesis (mitochondrial protein expression and mtDNA content) were 
evaluated. 
The imaging of cell growth showed that the aerobic glycolysis, hence glucose 
substrate, supports biosynthesis (cell growth) in both MTSs (Figure 6.4.1A-B), no 
growth occurred in both groups under glucose deprivation. Moreover, the results 
highlighted again that LF cells rely more on glutamine; indeed, we found 
glutamine deprivation to be limiting specifically for this fork. Interestingly, 
glutamine dependence could also be observed in UF cells, but only in the 
absence of pyruvate. Indeed, the results showed that reduced glutamine slows 
down the growth in both subtypes indicating its importance for the cell growth, 
but if the effect could be rescued in the UF after pyruvate supplementation, it 
was not in the LF (Figure 6.4.1A-B). Altogether, we have found that LF cells 
exploit better glutamine in contrast to cells of the UF group, which are able to 
use glucose or pyruvate even in the absence of  glutamine for maintaining cell 
growth. 
Next, looking at the functional results from both ATP and mitochondrial 
membrane potential measurements, we observed again that two MTSs 
differently utilise glucose and glutamine substrates. Moreover, we gained more 
insight into the role of the primary TCA cycle substrate pyruvate, exerting diverse 
effects in the upper and lower fork. 
In particular, we found the ATP production derives almost completely from 
glycolysis after both acute and adaptive response (Figure 6.4.2A-B), so the 
mitochondrial contribution to the energy production is limited (Figure 6.4.2C), 
indicating that both MTSs are primarily glycolytic. This suggesting that a major 
role of mitochondria in MTSs is to supply metabolic intermediates for 
biosynthesis but not for basal cellular energetic needs. In support of this 
observation, two papers have been published revealing that the despite of the 
best known role of mitochondrial ETC is the ATP synthesis, the essential function 
of the respiratory chain is making aspartate, claiming that proliferating cells 
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adjust their metabolism to support aspartate biosynthesis even at the expense of 
ATP synthesis (Van Vranken JG & Rutter J, 2015; Sullivan et al., 2015; Birsoy et al., 
2015). In addition, our results evidenced different substrate usage between the 
two MTSs for ATP production; indeed, LF was sensitive to glutamine deprivation 
with a consequent decrease of the ATP production, independently from the 
presence of glucose (Figure 6.4.2A-B); on the other hand, the primary TCA cycle 
substrate pyruvate was able to increase the ATP synthesis only in the acute 
response of the UF (Figure 6.4.2A-B). Form the mitochondrial membrane 
potential analysis, glucose deprivation caused depolarisation only in the UF, 
indicating a glucose dependence of this subtype and the utilisation of glutamine 
to sustain the membrane potential in the LF when glucose is limiting. On the 
other hand, glutamine deprivation induced depolarisation in both MTSs. 
Interestingly, during glutamine deprivation pyruvate was able to sustain Δψm in 
the LF but not in the UF. This suggest again that pyruvate acts in the MTSs at 
different level. 
Finally, we observed that long term glucose deprivation induced the expression 
of OXPHOS components, conferring adaptive phenotype. Indeed, the expression 
of Complex I increased in both forks (Figure 6.4.3A-B), but in different way 
between upper and lower fork. UF upregulated both CI and GAPDH, indeed the 
normalisation of CI to the glycolytic enzyme revealed no changes, indicated a 
coordinate expression of both proteins; the CI content was unchanged referring 
to grp75, suggesting it goes up with the whole organelle. On the other hand, LF 
simply increased CI content considering all the normalisations done (β-tubulin, 
grp75, GAPDH) (Figure 6.4.3A-B). Overall, mitochondrial biogenesis was induced 
in both MTSs by substrate deprivation but with different features in the UF and 
LF groups. The activation of biogenesis was confirmed also by the increase of the 
mtDNA content, in all the deprivation condition tested (Figure 6.4.3C), and in 
particular the increase was higher in the LF (Figure 6.4.3D). This difference 
probably relies on the different mitochondrial content between the two forks at 
basal condition, in which UF has higher mitochondrial content compared to the 
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LF, rendering UF more prone to respond under deprivation; on the other hand, 
LF needs to increase more the mitochondria content to face disadvantageous 
conditions. 
Overall, the data we presented in my thesis provide a first metabolic and 
bioenergetics characterisation of the newly identified Mitochondrial Tumour 
Subtypes in breast cancer, which have been identified according to their nuclear-
encoded mitochondrial transcriptional pattern. Experimental analysis confirmed 
different mitochondrial status at both protein and functional level between UF 
and LF type breast cancer cells. Moreover, metabolic analysis and deprivation 
experiments revealed that UF and LF mitochondria are differentially coupled to 
cellular metabolic pathways. Mitochondria in UF cells better exploit glucose 
derived substrates, whereas LF mitochondria preferentially use glutamine, 
opening to the new concept of the substrate preference, a new insight in the 
study of cancer metabolism. In conclusion, we provide evidence that the 
mitochondrial biogenesis patterns associated with mitochondrial tumour 
subtypes drive nutrient choice in breast cancer model. 
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8. SIGNIFICANCE 
 
Breast cancer is a heterogeneous disease involving many transcriptional 
alterations; however, so far it has never been assessed according to the 
mitochondrial profile of the tumours. 
Reprogramming of cellular metabolism and bioenergetics is one of the leading-
edge hallmarks of cancer, in which mitochondria play a central role driving 
tumour adaptation and evolution. 
The identification of new breast cancer subtypes according to their nuclear-
encoded mitochondrial transcriptional signature, called as Mitochondrial Tumour 
Subtypes (MTSs), upper fork and lower fork, provide a new classification system 
to exploit in the field of breast cancer. 
The characterisation of the UF and LF subtypes, defined by a specific 
mitochondrial transcriptional signature, revealed an associated mitochondrial 
biogenesis pattern that drives nutrient choice, or substrate preference, with 
related metabolic program important for the adaptation, thus providing a new 
insight in the complex hallmark of caner metabolic reprogramming. 
Further characterisation of MTSs to understand how to exploit mitochondrial 
biogenesis for cancer diagnosis and therapy represents a new challenge.  
Ultimately these studies are aimed lead to (i) development of novel strategies to 
target cancer by inhibiting mitochondrial biogenesis and (ii) the discovery of 
novel biomarkers to identify cancers where mitochondrial targeting is feasible 
will become future goals. 
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